Targeted delivery and MRI tracking of magnetically labelled cells by Riegler, J.
  
Targeted delivery and MRI tracking of 
magnetically labelled cells 
 
 
Johannes Riegler 
 
 
Submitted for the degree of 
Doctor of Philosophy in Bioengineering 
 
September 2011 
 
 
 
 
 
 
Centre for Mathematics and Physics in the Life Sciences and Experimental Biology 
(CoMPLEX) 
and 
Centre for Advanced Biomedical Imaging (CABI), Department of Medicine and Institute 
of Child Health  
University College London 
2 
 
Declaration 
I, Johannes Riegler, confirm that the work presented in this thesis is my own work, except 
where stated otherwise in the text. This work is based on research which has been conducted 
by me, during the time period from October 2009 to August 2011 at the University College 
London. 
 
 
 
 
Johannes Riegler 
 
13th of March 2012 
  
3 
 
Abstract 
The realisation of the therapeutic potential of cellular therapies will depend on our 
ability to deliver these cells to selected positions in the body where they can find a suitable 
micro-environment to flourish. Additionally our scientific understanding would befit from 
studies which can assess the behaviour of cells at specific locations inside the body. 
 Magnetic cell delivery is a potential technology which might allow realising these 
premises. The major advantage of magnetic delivery compared to other delivery strategies is 
the ability to spatially localise entities in the body via externally applied magnetic fields. 
However, the fast decline of these fields with increasing distances is posing a major challenge 
for its in vivo application.  
 The aim of this thesis was to investigate potential magnetic delivery approaches which 
can circumvent some of the typical limitations of this technique. Two different approaches 
were explored to this end. The first approach was evaluating the feasibility of a magnetic 
resonance imaging (MRI) system to steer labelled cells in arteries. Such an approach could take 
advantage of the imaging capabilities of magnetic resonance systems and combine these with 
steering to interactively guide cells or other entities of interest to a target area.  
 The second approach was addressing the feasibility of theoretical optimisations and the 
scalability of experimental results. For that, human MRI data was used to derive geometrical 
models of the blood vessels to which cells were to be delivered in this scenario. Finite element 
modelling was then used to explore potential magnet arrangements with the aim to maximise 
the force acting on cells over all target vessels. The best performing arrangement was then 
used for computational fluid dynamics simulations to test the possibility of cell capture from 
the flowing blood stream. Finally the possibility to scale-down such an arrangement to the 
dimensions of an animal model without changing the forces acting on cells was investigated.  
 Cells have to be labelled with magnetic materials in order to allow their magnetic 
actuation. This magnetic materials cause a distinctive contrast on MRI images. The potential of 
this imaging modality for cell tracking has been illustrated with an in vivo example for cell 
tracking in a rat heart and an in vitro example for a tissue engineering application.  
 Experiments with a preclinical MRI system illustrated the feasibility of cell steering with 
MRI indicating that such an approach could be useful for magnetic cell delivery. Computational 
models for the evaluation of magnet arrangements allowed the in-silico assessment of their 
potential and could be used to improve the experimental design of pre-clinical studies.   
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Introduction to the layout of this thesis  
 
This thesis consists of 8 chapters whereby the first three chapters give some theoretical 
background and motivation for the conducted work. The experimental chapters 4-7 start with 
a brief introduction laying out additional background information which has not been stated in 
chapters 1-3. Each of the experimental chapters contains Materials and Methods relevant to 
the particular chapter. This is followed by Results, Discussion and Conclusion. General 
conclusions and future directions are given in chapter 8. 
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1 The potential of cellular therapies for vascular diseases 
Vascular diseases have a high prevalence in the industrialised world and have 
now become the most common cause of death globally. Vascular diseases include 
myocardial infarction, peripheral arterial disease and stroke. All of these diseases lead 
to extensive cell death in effected organs exceeding the natural regenerative potential 
of these organs. The discovery of stem cells has sparked hopes to use the high 
regenerative potential of these cells to replace the dead cells and repair the effected 
organs. This chapter provides an overview over the diseases of relevance for this thesis 
and the current state of cellular therapies for each of them. Most of these cellular 
therapies require the ability to deliver cells to a specific location and monitor their 
behaviour at that location. Problems related to that will be highlighted as they are the 
primary concern of this thesis. At the end of the chapter a brief definition will be given 
for cell types used for this thesis. 
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1.1 Vascular diseases and stem cell therapies 
1.1.1 Myocardial infarction 
Coronary artery disease is the most common cause of death in the 
industrialised world1. Coronary artery disease leads to reduced blood supply of the 
myocardium leading to ischemia (heart attack). Cardiac ischemia causes a chain of 
events starting with cell death, inflammation, scar tissue formation and remodelling 
which ultimately leads to heart failure. Despite the improvements due to drugs such 
as statins the only long term cure is heart transplantation.  
The discovery of stem and progenitor cells has led to new hopes that a 
regenerative medicine approach might be able to restore cardiac function and 
prevent heart failure. This hope rests on the hypothesis that stem cells or progenitor 
cells might be able to replicate and differentiate into cardiomyocytes as well as 
vascular cells replacing dead cells and functionally integrate with neighbouring cells. 
In order to test this hypothesis two principle strategies might be tested. Firstly it 
might be possible to mobilise stem or progenitor cells in situ in the heart or 
hematopoietic system (provided they have sufficient trans-differentiation potential) 
in sufficient numbers to achieve meaningful repair. Or alternatively externally 
amplified cells of autologous or homologous origin delivered to the site of injury 
might be able to survive and functional integrate into the existing tissue.  
Most of the research so far has focused on the cell delivery approach. The 
potential advantages of such an approach are better control over the cell type, 
amplification potential, delivery time, delivery route, delivery site and potentially 
genetic manipulation. Potential disadvantages are higher costs (GMP facilities), 
availability of controlled and approved culture media, ensuring cell stability and 
identity and the risk for immune reactions and teratoma formation depending on the 
cell type used. All of the above points are research questions for which we have 
currently no answers.  
The question to start with for a cell delivery approach is: what is the optimum 
cell type? Conceptually ESCs would offer the greatest potential as they should be 
able to form new cardiomyocytes and blood vessels due to their totipotent nature. 
However, this versatility comes with a high risk of teratoma formation and ethical 
question of potential ESCs sources (ESCs are derived from the inner cell mass of 
blastocysts (embryos)). ESCs and human ESCs (hESCs) have been used in animal 
experiments where they showed the ability to repair the AV node2;3 and improve 
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cardiac function4-6. Human ESC derived cardiomyocytes were able to survive and 
maturate in immunodeficient rats and mice for at least 12 weeks6. However, 
transplanted cells were surrounded by fibrotic tissue which separated them from the 
host myocardium. Functional integration of hESC derived cells could not be observed 
in rodents7 which might be explained by the differences in their heart rates. The 
improved cardiac function is hence most likely due to paracrine effects (the release 
of small signalling molecules) as has been observed for other cell types.  
Bone marrow cells (BMCs) (from bone marrow aspirations) and mesenchymal 
stem cells (MSCs) (isolated from the bone marrow, peripheral blood, adipose tissue 
or amnion) have been used most frequently for cell transplantation experiments in 
animals8-10. BMCs are a mixed population of cells containing hematopoietic stem and 
progenitor cells (multipotent) as wells mesenchymal stem cells (multipotent). 
Mononuclear cells (MNCs) are hematopoietic progenitors of macrophages. This 
subpopulation of BMCs will be used as a model cell type together with MSCs in 
chapter 4. Functional improvements have been reported in most of these cell 
transplantation studies but cell survival is generally poor and strong inflammatory 
responses have been observed by some. Cell differentiation and integration seem to 
be a rare event and positive effects are most likely due to paracrine effects11. BMCs 
and MSCs have been used phase 1 and phase 2 clinical trials12;13. These trials showed 
only marginal improvements in cardiac function, generally less than 5% of ejection 
fraction (pumping efficiency of the heart). These are modest effects compared to 
some animal experiments indicating the need for improved animal models and 
assessment standards.  
Particular pressing questions in the context of cell delivery after myocardial 
infarction are: i) what is the right microenvironment to promote cell survival and 
differentiation, ii) do we have to suppress scar formation, iii) should cells be 
delivered before or after the inflammatory phase? A question which is of particular 
interest in context of this thesis is the need for an optimised cell delivery strategy. 
Currently used intravenous delivery strategies are inefficient and retain less than 5 % 
of cells in the heart14. This can lead to unwanted side effects such as micro emboli in 
lung and brain and loss of precious cells. Even direct injection into the myocardium 
has a low retention efficiency but this might be improved via magnetic targeting15. 
Potential methods for magnetic cell delivery will be discussed in chapters (2 and 4) 
while cell tracking will be illustrated in chapter 7. 
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The discovery of progenitor cells in the heart16 and evidence for the trans-
differentiation potential of haematopoietic cells towards cardiomyocytes8 has led to 
hopes that it might be possible to increase the regenerative potential of an adult 
human heart. This is particular appealing as the delivery of small molecules or 
proteins might be sufficient to realise that potential without the need for cell 
transplantation and the problems associated with it. However, it needs to be proven 
that this repair potential is sufficient and that it can be activated without causing cell 
growth in other organs.  
1.1.2 Atherosclerosis 
Peripheral arterial disease (PAD) is one of the major manifestations of 
atherosclerosis leading to the obstruction of blood flow in major arteries, most 
commonly in the pelvis and legs. Prevalence of PAD is approximately 12% for people 
of more than 60 years of age in the United States, leading to at least 8 million 
Americans affected17. Major risk factors for PAD are similar to those for 
atherosclerotic diseases in the heart and brain such as advanced age, smoking, 
diabetes, dislipidema (high blood cholesterol levels) and hypertension. With aging 
populations and a rise in diabetes in the industrialised world there is an increasing 
prevalence of PAD18. Although PAD is predictive for other cardiovascular events many 
patients are asymptomatic as other complications such as stroke or heart disease 
dictate patient symptomatology19. In those who are symptomatic, it presents with 
progressive cramp in the calves on walking (intermittent claudication).  
PAD can lead to critical limb ischemia, particularly in diabetics, where the 
limb is chronically undersupplied with oxygen and nutrients. Symptoms of critical 
limb ischemia are rest pain, cold or numb feet and non healing ulcers or gangrene. 
Diabetic PAD is the leading cause of amputation in the Western world.  
Treatment of PAD includes life style changes, exercise and risk factor 
modification. Intervention to alleviate symptoms and prevent amputation require the 
restoration of pulsatile blood flow to the feet20;21. This can be achieved via balloon 
angioplasty, stenting or surgical intervention such as bypass grafting or 
endarterectomy (surgical removal of a blockage). Catheter based interventions for 
angioplasty carry lower risks compared to surgery and reduce the duration of 
hospitalisation. However, despite initial improvements in blood flow, long term 
patency following angioplasty is limited by vascular restenosis and neointimal 
hyperplasia22;23. Neointimal hyperplasia, excessive growth of smooth muscle cells in 
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the blood vessel, is a response of the vessel wall to injury. Several potential solutions 
for this problem have been suggested including: drug eluting stents24, cellular 
therapies25;26 and specific surface coatings for stents27, which has led to some 
increase in patency.  
As traditional techniques are reaching their limits24;27, new avenues leading to 
cellular therapy via specific cell capture are currently being explored28. Drug eluting 
stents have shown promising results for short term outcome. However, the long term 
outcome did not improve as vascular healing is delayed29. In the last decade, cellular 
therapies have received more attention particularly since Ashara et al.30 discovered 
endothelial progenitor cells (EPCs) in the circulating blood.  
Endothelial progenitor cells are a population of bone marrow-derived cells 
which incorporate into sites of neovascularisation and endothelial injury. Animal 
studies indicate that the administration of EPCs to sites of vascular injury leads to re-
endothelialisation and prolonged vessel patency25;26;31. Another area of PAD for 
which cellular therapies have been tested in clinical trials is to improve 
collateralization (small blood vessel bridging areas where major blood vessels are 
blocked start to expand in number and diameter) and neoangenesis (the formation 
of new blood vessels). Most of these trails have used either BMCs or EPCs32. There is 
some evidence that these therapies with direct cell injection into the muscle may act 
in a paracrine manner increasing the mobilisation of resident progenitor cells33. For 
cellular therapies with the aim to improve re-endothelisation, the rarity of EPCs and 
other potential cells combined with low retention efficiencies in arteries poses 
significant difficulties. Furthermore, EPC concentrations and activity are reduced in 
patients with PAD due to the associated risk factors34; taken together this results in a 
suboptimal therapy. There is a clear clinical need to develop a therapeutic strategy to 
target these cells to the area of need and maximise their retention. A potential 
solution to ensure localised cell delivery and retention with high efficiency will be 
shown in chapter 6. 
1.1.3 General considerations for cell based therapies 
Cellular therapies, particular stem and progenitor cell based therapies offer 
unprecedented potential for new therapies. In order to unlock this potential it is 
necessary to develop a better understanding of potential risks and benefits in order to 
define acceptable risk limits for each potential application and advance from 
preclinical to clinical trials.  
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 The complexity of cellular therapies and their wide range of potential 
interactions with the recipient organism will need new assessment criteria for 
preclinical and clinical safety evaluation. This safety issues concern primarily the 
following points: manufacturing consistency, identification / removable of 
undifferentiated cells, genetic stability, delivery route / device, biodistribution, 
tumorigenicity, immunogenicity, and clinical / preclinical endpoint assessment.  
 Manufacturing consistency should ensure that the cell product in its final 
formulation is always within specification. In order to achieve that, assays need to be 
established which can test for cell activity, purity, differentiation status, and more 
conventional tests to ensure the product is free from contaminations including viruses 
and prions. Good manufacturing practice will additionally require the full 
characterisation of all materials used during production which might be difficult if not 
chemically defined materials such as serum are needed. Achieving manufacturing 
consistency will be particular challenging for products which are based on the 
extensive expansion of autologous or allogenic cells as compared to a stable cell line 
which is to be used for many patients. 
 Identifying and removing undifferentiated cells will be part of the 
manufacturing process but deserves special considerations as tumorigenicity is one of 
the major safety concerns. Efficient differentiation procedures will be necessary as well 
at test procedures which are sensitive enough to detect small numbers of 
undifferentiated cells (e.g. PCR for specific genes) und means of removing them.  
 Extensive expansion of cells in vitro leads to the accumulation of mutations 
and genetic instability including chromosomal aberrations. As chromosomal 
aberrations are considered a hallmark of cacner35, tests for chromosomal integrity and 
potential mutations need to be part of the final product screening. In addition to these 
random events there is evidence for inherent instabilities in ESCs , adult stem cells and 
induced pluripotent stem cells (iPSCs) 36-38. Most of this changes are time depended. It 
might hence be necessary to define an acceptable culture time or number of 
population doublings to reduce the risk of genetic instability. 
 There are many different possibilities to deliver manufactured cells. Preclinical 
testing should assess and identify the optimum delivery strategy for each particular 
treatment application. The selected delivery device needs to be tested together with 
the final product before it can be used clinically. Such a device might also need 
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approval. Safety considerations for a delivery device have to include potential 
accumulation at non target sides and increased difficulties to track cells if delivered 
into the circulatory system.  
 Depending on the route of delivery it might be necessary to assess only one 
organ system or the whole body to estimate the bio-distribution. This should ideally be 
done with highly sensitive and specific imaging modalities. It would also be desirable if 
that could include monitoring gene expression and differentiation status. In order to 
assess the latter aspect, genetic modification to introduce a marker gene might be 
necessary. Of course it needs to be established, that this does not interfere with 
therapeutic cell function. Once the question of bio-distribution has been assessed in a 
preclinical model, suitable means for cell tracking in the clinical setting have to be 
established. Additional considerations of potential long term immunogenic effects of 
marker gene expression in humans need to be considered. 
Tumorigenicity is the biggest risk factor for stem and progenitor based 
therapies as the potential to form teratoma is part of their defining characteristics. As 
mentioned above ensuring undifferentiated cells are not part of the final product is 
essential. This risk is difficult to assess in preclinical models as most of the will be using 
immune suppression. Careful assessments to quantify that risk in clinical trials will be 
necessary. A recent report about a donor derived brain tumour which has been 
detected after neural stem cell transplantation has highlighted this problem39. In order 
to control this risk the insertion of an activatable apoptosis gene might be necessary40. 
However, this will raise additional regulatory hurdles as cells might be classified as 
genetically modified organism and cellular therapies. 
Immunogenicity is the second biggest risk factor following tumorigenicity. 
Although some stem cells show some immune privileges it is questionable if that is the 
case for their differentiated progeny. This will be less of an issue if iPSCs prove suitable 
for clinical applications. In order to get a better understand of that risk, analogous cells 
could be derived and tested in animal models. But this can only partially address this 
problem.  
 All above mentioned risks have to be compared against potential patient 
benefit. Defining suitable criteria for the assessment of treatment success is hence 
very important. Ideally such criteria should be easily and unambiguously measurable in 
both animal model and humans. These criteria should be standardised across 
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preclinical experiments and clinical trials. An example of unnecessary confusion and 
ambiguity can be found in the field of cellular therapies for myocardial infarction were 
a range of methods that are not easily comparable from histology to MRI has been 
used.  
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2 Magnetic delivery of biological entities 
Chapter one provided an overview over some vascular diseases and the 
potential of cellular therapies for them. As indicated previously, efficient cell delivery is 
necessary for the success of such interventions. Efficient cell delivery and retention 
might be achieved via magnetic targeting. This chapter will therefore give a general 
description of concepts related to magnetism which are used throughout this thesis. 
Following these basic definitions, different applications of magnetic particles in the 
field of medicine will be discussed. These include magnetic separation, magnetic cell 
and drug delivery, magnetic hyperthermia and finally magnetic cell tracking via 
magnetic resonance imaging. 
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2.1 Definitions and basic principles 
2.1.1 Magnetic fields 
A magnetic field is an area of space with increased energy density and an 
energy gradient to its surrounding. A magnetic field can be detected via the force it 
exerts on a moving charge (Lorentz force), the torque on a magnetic dipole or the 
alignment of electron and nuclear spins. The most common phenomena of these is 
the reorientation of a magnetic needle (dipole) by the magnetic field of the earth.  
The Lorentz force is given by 
            ,                  Eq. 2.1 
with   the charge in Coulomb,   the velocity in m/s and  the magnetic flux density 
in Tesla. 
Magnetic fields are produced by moving electrical charges or the interaction of 
spin and orbital moments of electrons. Magnetic fields due to current carrying 
conductors are an example for the former case while permanent magnets are an 
example for the latter. Although permanent magnets cannot be explained 
adequately without quantum mechanics a classical explanation can be given by 
considering electrons as circulating current loops. Magnetic fields generated by time 
invariant moving electrical currents can be described by the Biot-Savart law: 
      ∫
  
  
 
      ̂
  
                   Eq. 2.2 
where    is the permeability of free space,   the current in Ampere,   the vector of 
the current carrying element,  ̂ unit vector to and   the distance between conductor 
element and field evaluation point. 
The most important equations for magnetism are the Maxwell equations 
which unified several existing laws from Gauss, Ampere and Faraday. Maxwell’s four 
famous equations showed that electricity and magnetism are coupled phenomena 
and that light is a form of electromagnetic radiation. These four equations are given 
in differential form with their names as: 
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Gauss’s law of electric fields 
        
 
  
  ,                  Eq. 2.3 
Gauss’s law of magnetic fields 
           ,                  Eq. 2.4 
Faraday’s law 
         
  
  
    and                 Eq. 2.5 
the Ampere-Maxwell law 
          (    
  
  
)   ,                Eq. 2.6 
with   the electric field in V/m,   the charge density in C/m3,    the electric 
permittivity of free space and   the electric current density in A/m2. 
For this thesis we are mainly concerned with equations 2.4 and 2.6 from which 
some basic properties of magnetic fields can be deduced. Gauss’s law shows that the 
divergence of magnetic fields is zero at any point. This means that the net magnetic 
flux going through any real or imaginary surface is zero. This is a direct consequence 
of closed magnetic field lines and the non-existence of magnetic monopoles. The 
Ampere-Maxwell law states that a circulating magnetic field is generated by an 
electric current and time variant electric fields. This was first discovered by Oersted 
when he saw that a current running through a wire led to the deflection of a compass 
needle next to it. 
The unit for the magnetic field strength  is A/m which follows from its 
definition as the field produced in the centre of a current loop with 1 meter in 
diameter carrying one Ampere. Defining the magnetic field strength in this way is 
useful to distinguish between the applied field and the magnetic flux density or  
field which gives the magnetic response at a particular point due to the presence of 
  and matter. The relation between magnetic induction and magnetic field is given 
by 
        (   )   ,                 Eq. 2.7 
with    the permeability of space (     
      ) and  the magnetisation of 
the material in A/m.  
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2.1.2 Magnetic properties of matter 
Materials can be classified according to their response to an external magnetic 
field. A dimensionless parameter to describe this is the magnetic susceptibility which 
is defined as 
      
 
 
   .                  Eq. 2.8 
Materials with a negative susceptibility (typically ≈-10-5) are classified as diamagnetic 
while materials with small positive values (10-2-10-5) are classified as paramagnetic. A 
special class of ferromagnetic materials are antiferromagnetic materials which show 
also low suseceptibilites. High suseceptibities (102-105) are observed for 
ferromagnetic, ferrimagnetic and helimagnetic materials. 
Diamagnetism is caused by changes in the orbital motion of electrons due to 
the presence of a magnetic field. This leads to a weak magnetisation which opposes 
the external magnetic field. Diamagnetism is present in all atoms but can only be 
observed in materials which show no other form of magnetic behaviour for example 
copper, silver, bismuth and water.  
Paramagnetism is caused by the alignment of atomic magnetic moments with 
the external field. The spin of unpaired electrons is the primary source of the atomic 
magnetic moment with contributions from orbital angular momentum. Magnetic 
moments do not interact in paramagnetic materials and are randomly orientated due 
to thermal reorientation when the thermal energy is higher than the magnetic. This 
makes the susceptibility inversely temperature depended. The magnetisation of 
paramagnets is proportional to  for a low field strength but reaches saturation at a 
high field strength. Typical materials for this group are aluminium, magnesium and 
oxygen. 
Ferromagnetism is observed in metals such as iron, nickel, cobalt and some 
rear earth elements. It is caused by the interaction of atomic magnetic moments 
from unpaired electron spins leading to the alignment of moments over big regions 
called domains. Moments are aligned parallel in domains due to the exchange 
interaction of spins but different domains have different random alignment. If they 
are exposed to external magnetic fields, domains boundaries start to move and 
increase the net alignment of all domains parallel to the external field. Increasing the 
temperature beyond a critical temperature the so called Curie temperature increases 
the thermal energy beyond the interaction energy leading to paramagnetic 
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behaviour. Ferromagnetic materials can retain their magnetisation (residual flux 
density Br) once they have been magnetised. This magnetisation can be reversed 
with a big enough magnetic field, by the coercive force  . They also show signs of 
magnetic memory which is called hysteresis. Another characteristic phenomenon of 
ferromagnetism is the saturation magnetisation MS which is the maximum 
magnetisation which can be achieved. B-H curves are frequently used to illustrate the 
complex behaviour of ferromagnetic materials. The crystal structure of these 
materials has an influence on molecular interactions and causes non-isotropic 
magnetic behaviour. 
Antiferromagnetism is found in materials with particular crystal structures 
leading to antiparallel alignment of magnetic moments between sublattices and 
parallel alignment within. As these magnetic moments between sublattices are 
equal, antiferromagnets show no net magnetisation in the absence of a magnetic 
field. This magnetic behaviour is commonly found in transition metal oxides such as 
FeO, CoO and MnO. Antiferromagnets show also a transition from an ordered state 
to an unordered state similar to the Curie temperature, which is called Neel 
temperature. 
Ferrimagnetism is a special case of antiferromagnetism where the magnetic 
moments of sublattices are unequal resulting in a net magnetisation. Sublattices can 
be made up by different ions e.g. Fe2+ and Fe3+ separated by oxygen. They show 
hysteresis, saturation magnetisation and a Curie temperature at which the ordered 
state is lost as in ferromagnetic materials. Some of the materials have a temperature 
below the Curie temperature where the magnetic moments of the sublattices are 
equal, the magnetisation compensation point. Ferrimagnetism was discovered in 
ferrites such as: Fe3O4, γ-Fe2O3 and MO*Fe2O3 with M being a transition metal.  
Superparamagnetism is found in ferro- and ferrimagnetic nanoparticles where 
the particle core consists of a single magnetic domain. This allows for random 
reorientation of the magnetisation orientation due to thermal energy. The mean 
time between these re-orientations is called Neel relaxation time. 
Superparamagnetic particle retain no magnetisation after the removal of a magnetic 
field but exhibit magnetisation similar to paramagnets in a magnetic field. However, 
their magnetisation is much higher than observed for paramagnets and they show 
saturation similar to ferro- and ferrimagnetic materials. The magnetisation as a 
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function of the applied field can be approximated by a Langevin function (see 
equation 2.13).       
Helimagnetism is found in materials with a crystal structure leading to 
ferromagnetic and antiferromagnetic interactions. Magnetic moments are aligned 
parallel in one crystal plane while subsequent planes have their moments inclined at 
an angle leading to a helical structure. This form of magnetism can be observed in 
dysprosium, holmium, terbium and other rare earth elements at low temperatures. 
2.1.3 Magnetic forces 
Gauss’s law for magnetic fields shows that magnetic moments can only exist as 
magnetic dipoles. The dipole moment  of a loop with current   is a vector normal 
to the plane of the loop given by 
              ,                  Eq. 2.9 
with   being the radius of the current loop. The magnetic field of a bar magnet and a 
current loop are similar and can also be represented by two magnetic poles   
separated by distance   giving, 
           .               Eq. 2.10 
Descriptions of the magnetic moment as a current loop or a magnetic dipole are 
interchangeable. However it has to be remembered that a current loop has no 
effective pole separation while a dipole has no effective cross section. 
A magnetic moment experiences two forces in a magnetic field: a torque to 
align its dipole moment and a translational force towards regions of high flux density 
if a field gradient is present. The torque is given by 
              ,               Eq. 2.11 
while a translational force is given by 
       (     )    .              Eq. 2.11 
For biological applications of magnetic particles it is convenient rewrite the above 
equation as41  
       
     
  
(   )    .              Eq. 2.12 
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with    being the volume of magnetic material and    the susceptibility difference 
between the magnetic material and its surrounding medium. As mentioned in section 
2.1.2 the susceptibility is only directly proportional to the magnetic field for 
paramagnetic materials. However, the most commonly used materials for magnetic 
particles are iron oxides that show ferrimagnetic behaviour. It is hence necessary to 
replace    by a function that models this behaviour such as the Langevin 
approximation: 
              ( )  
 
 
  and               Eq. 2.13 
       
       |
 
  
|
    
 ,                 Eq. 2.14 
whereby   is the saturation magnetisation of the particle,   the particle diameter, 
  temperature, |
 
  
| magnitude of the magnetic field strength and    Boltzmann’s 
constant.  
Magnetic particles for the context of this thesis are nanometre to micrometre 
sized particles with superparamagnetic (SPM) behaviour unless stated otherwise. 
This requires that crystal cores are in the size range of 10-30nm depending on the 
material and shape. The most common materials used are cobalt and iron whereby 
particles for biological applications are almost exclusively iron oxide particles.  
Widely used methods for particle synthesis are colloidal synthesis in organic 
solvents and co-precipitation of Fe2+ and Fe3+ by a base in aqueous solutions42. These 
synthesised crystals need to be stabilised to make them useful for biological 
applications. 
Important characteristics for the biological application are: low toxicity, 
biocompatibility, non-aggregating, high saturation magnetisation, no remnant 
magnetisation, monodispersity, chemical stability and low unspecific interaction with 
other biological entities. In order to achieve these properties iron oxide crystals are 
coated with suitable substances such as dextran, cellulose, alginate or peptides. 
These polymers can also be used to manufacture bigger particles by embedding 
several iron oxide crystals in one particle. Further modifications of particles surfaces 
can be performed to achieve specific binding to epitopes via antibodies or peptides, 
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absorption of nucleic acids via positive charges, attachment of drugs via organic 
linkers and others43-46.  
Another important parameter for magnetic particles is their hydrodynamic 
diameter that determines the drag force on particles, internalisation route for cell 
labelling and half-life time and clearance route in vivo47. The latter two phenomena 
are of course strongly influenced by other surface characteristics such as charge, 
hydrophobicity and molecular moieties. 
2.2 The application of magnetic particles in medicine 
2.2.1 Magnetic separation 
Magnetic separation uses inherent or externally provided magnetic moments 
attached to the entities of interest in order to separate these entities from their 
surrounding media which has a very weak magnetic moment or is diamagnetic. 
Major advantages of magnetic separation are: high speed, direct extraction of 
entities of interest from complex media such as blood and food, extraction of 
substances from very dilute media, compatibility with downstream analysis 
techniques (e.g. immunohistochemistry and PCR) and it is a fairly cheap technique. 
These advantages led to widespread uses in life sciences applications with 
commercial companies providing a range of separation products.  
Only a few biological entities such as red blood cells48;49 and magnetotactic 
bacteria50;51 have sufficient natural magnetic moment for their magnetic separation. 
All other entities need to be labelled with magnetic substances. Several magnetic 
substances such as magnetic proteins (ferritin)52;53 and magnetic particles41;54-63 have 
been used. However, magnetic nano- and micro-particles with superparamagnetic 
behaviour are used most frequently. In most cases affinity ligands with high 
specificity are used to separate the entities of interest such as: proteins64;65, 
cells55;56;60;61, viruses66;67, ribonucleic acids54;68, cell organelles57, phages69;70 and 
spermatozoa71. These affinity ligands: antibodies, peptides or organic molecules are 
attached to magnetic particles via adsorption72, covalent binding73;74 or electrostatic 
interactions74. Depending on the aim, direct or secondary labelling procedures might 
be used. An example for direct labelling in the context of cell isolation would be an 
antibody against a specific cell surface receptor attached to a magnetic particle. In 
the indirect case, a combination of a primary antibody and a secondary antibody 
attached to the magnetic particle would be used. Indirect labelling strategies have 
30 
 
the advantage that a range of different antibodies can be used to increase the 
specificity for the selected cell. This is particular useful when surface epitopes are not 
highly expressed. A direct method is usually faster and requires fewer antibodies. In 
the case of cell separation specificities of up to 99.9% and 3 log depletion efficiencies 
have been reported75;76.  
After the labelling step, entities of interest with an attached magnetic particle 
need to be separated from the media. This can be achieved in batch mode in the 
simplest case by the placement of a permanent magnet next to the tube. More 
sophisticated separation devices are available which use columns filled with soft 
magnetic spheres or steel wool and an external magnetic field to generate high field 
gradients77. Other high field gradient devices such as quadrupole and hexapole 
magnet configurations have been used as well78. Additionally continuous separation 
systems using fluidised bed designs and others have been reported79. 
Following the separation step, an additional step for the removal of the 
magnetic label might be necessary. This can be achieved for cells in simple cases via 
cultivation and the addition of media but might involve enzymatic cleavage of the 
label, active displacement of the label via competitive binding or ionic exchange. Cell 
viability is normally not negatively affected by magnetic separation techniques due to 
suitable pH values in the buffered separation media and the low magnitude of the 
forces used61;73.  
In general it can be said the magnetic separation is a highly versatile fast, 
efficient and simple separation method suitable for biomedical applications. 
2.2.2 Magnetic drug and cell delivery 
The increased understanding of human diseases and the development of drugs 
for their treatment has been the basis for the success of medicine in the 20th century. 
This is most evident in the field of infectious disease where small molecules globally 
administered eradicate microorganisms without side effects. However, most drugs 
do act on non-diseased cells in the body and cause unwanted side effects. For 
example cancer drugs aimed at fast growing cancer cells kill other fast growing cells 
such as haematopoietic cells, epithelia cells and hair follicle cells.  
Research efforts are accordingly directed towards the development of 
targeted therapeutics80. Ideally, these therapeutics should only interact with 
pathological cells. One possibility to achieve that is the use of molecular recognition 
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via specific binding or the use of pro-drugs which are activated in a specific 
environment. Another possibility is the use of physical forces to spatially localise a 
drug. Magnetic delivery strategies are promising candidates for that, as magnetic 
fields can penetrate the human body without generating significant forces on normal 
cells. 
The basic principle behind magnetic delivery strategies is to label drugs or cells 
with a magnetic entity, in order to make them responsive to a magnetic field, 
followed by the application of a magnetic field gradient to concentrate the drug or 
cell at the area of interest41;81;82. 
Accordingly the first step for magnetic drug or cell targeting is the magnetic 
labelling. Common requirements for these magnetic labels are superparamagnetic 
behaviour to avoid aggregation of particles which could cause embolisms, 
biodegradability, high saturation magnetisation, low toxicity and high reproducibility 
in all manufacturing stages.  
Magnetic drug delivery adds additional requirements such as long blood half 
live time, no immunogenicity, functionalisation potential for drug attachment and 
controlled release or porosity if the drug is loaded via absorption83. Drug attachment 
to a magnetic particle has to be primarily concerned with the release kinetics and 
release mechanism. A whole range of release mechanisms from diffusion84 to 
controlled release85-87 are available. Magnetic particles are here mainly a carrier but 
their route of clearance, degradation and potential interference with the drug have 
to be addressed. 
For cell labelling appropriate charges for attachment or specific receptor 
ligands for active uptake are necessary88;89. Small hydrodynamic diameters are 
generally favourable as they allow for higher iron concentration in cells due to more 
efficient uptake. Size is also an important determinant of the uptake route with 
particles <200 nm being internalised via pinocytosis while bigger ones have to be 
internalised actively via endocytosis90. As different cell types have different 
phagocytic potentials additional means to increase cellular uptake such as 
transfection agents91;92, specific receptors ligands93;94, serum starvation, 
electroporation95 or magnetofection96 (forcing particles into cells via magnetic field 
gradients) might be necessary. The primary aim for magnetic cell delivery is to deliver 
biologically active cells to a specific place. It is hence important that labelling does 
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not interfere with the therapeutic potential of cells. In particular cell growth, 
differentiation and migration potential should not be influenced negatively. 
Additionally increases in mutation rates due to particle breakdown products or 
increased inflammation have to be avoided.  
The need for biodegradability has so far favoured iron oxide nanoparticles as 
the human body is able to degrade them and integrate the iron into the body iron 
pool47;97;98. Most studies have shown that iron oxide nanoparticles are well tolerated 
by cells below certain concentrations and do not negatively affect growth or 
differentiation potential10;43;88;92;99-106. Transient up-regulation of several hundreds of 
genes for up to two weeks following cell labelling with SPIONs has been reported107. 
There have also been reports indicating limited differentiation potential for some 
cells104;108. A potential mechanism for nanoparticle induced DNA damage has been 
reported, although not for iron oxide based nanoparticles109. There are no indications 
for long term health risks so far. Clinical studies with SPION labelled cells show that 
labelled cells are well tolerated without unwanted side effects103;110;111. However, the 
safety profile has to be assessed for each cell type and possibly even for each cell line 
separately.  
 Generating magnetic field gradients for the localisation of drugs and cells is 
the second step of magnetic targeting. A simple classification of different devices to 
generate field gradients is to divide them into three broad groups: permanent 
magnets, electromagnets and local flux concentrators. 
 Modern rear earth permanent magnets offer a high flux density without the 
need for power or cooling. The main disadvantage is the fast decay of the field 
strength with increasing distance to the surface. Another disadvantage might be the 
inability to dynamically change the field strength. These magnets can be used as 
simple blocks or more efficiently in arrangements which focus the magnetic field in a 
particular area such as Halbach arrangements112. Permanent magnets have been 
placed next to the body for magnetic drug and cell delivery in preclinical 
settings15;84;105;113-119 and for magnetic drug delivery in a clinical trial84. Animal studies 
with surgically implanted permanent magnets have also been reported120.  
 Electromagnets, mostly used with iron cores, offer the ability of dynamic field 
strength adjustments which can be used for dynamic control and active guidance. 
Their main disadvantages are substantial power and cooling requirements and similar 
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to permanent magnets, the fast decay of the field strength. Electromagnets have 
been used for clinical and preclinical drug targeting121-124 and their potential for 
dynamic control and active guidance has been demonstrated125. A special 
subcategory in the group of electromagnets are superconductors. Superconductors 
offer high flux density which can’t be achieved with electromagnets but don’t 
normally allow for dynamic changes of their field strength. The potential application 
of superconductors for magnetic targeting has been illustrated by in vitro 
experiments126;127. MRI systems use a combination of a superconductor and 
electromagnets. This combination has some advantages for magnetic targeting which 
have recently been shown in in vitro and in vivo experiments128-130. 
 In order to address the problem of the fast decay in magnetic field strength 
with increasing distances mentioned above, attempts have been made to use 
ferromagnetic objects to act as local flux concentrators. These flux concentrators 
need to be inserted into the body where they generate high field gradients locally 
when exposed to an external magnetic field. This enables the generation of sufficient 
forces for magnetic targeting at a depth in the body that would otherwise not be 
feasible. Experimental studies have shown the feasibility of this approach particular 
for applications where metal stents are used106;128;131-133. Such an approach could be 
used for magnetic drug and cell delivery for pathologies which require the 
deployment of stents. Experimental and theoretical work has been undertaken to 
extend this concept for guided delivery via the placement of needles next to blood 
vessel bifurcations to guide magnetic entities along or the used of use of shears as 
seed points to accumulate drugs134-136. 
 Magnetic delivery strategies have demonstrated their potential in preclinical 
experiments for drug delivery113;118;137, cell delivery106;117;119, nucleic acid 
delivery106;119;122;138, magnetofection139;140, viral delivery and blocking of the blood 
supply to tumours141. Additionally their potential in combination with hyperthermia 
(see section 2.2.3) and MRI (see section 2.2.4) has been demonstrated. New 
possibilities for the molecular control of cellular mechanisms and advanced 
applications in tissue engineering are emerging105;142;143 as well. However, their 
clinical success has so far been limited to MRI contrast agents and some early trails 
for drug delivery. One of the biggest problems already mentioned is the fast decline 
of magnetic force with increasing distances from their source. An additional 
limitation is the maximum flux density achievable in permanent and electromagnets 
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which make their translation from animal experiments to humans difficult. 
Theoretical modelling has been performed for some aspects of magnetic 
targeting114;134;144-146. However, a through theoretical basis addressing questions of 
suitable experimental designs which can be translated from animals to humans 
would be desirable. A first step towards that aim will be presented in chapter 6. 
 Potential clinical applications are also hampered by the lacking availability of 
clinical grade magnetic particles. Although magnetic particles have been used 
frequently for MRI, the production of these agents has been discontinued due to 
economic reasons. New SPION based contrast agents are currently in late clinical 
trials but they will only eliminate the problem partially. Particularly as requirements 
for MRI contrast agents are different from targeting or hyperthermia applications. 
Particles for research applications are available from several commercial companies 
but pharmaceutical companies have so far not invested in this area despite some 
commercial potential147.  
2.2.3 Magnetic hyperthermia 
Magnetic hyperthermia refers to the use of magnetic particles in combination 
with alternating magnetic fields to induced localised heat formation. It has to be 
differentiated form thermal ablation where temperatures of > 50°C are used to 
destroy cells and tissues. Magnetic hyperthermia aims to achieve temperatures of 
>42°C to selectively damage cancer cells and induce apoptosis. Another application 
of magnetic hyperthermia is the controlled release of drugs. 
Magnetic materials can generate heat via different mechanisms: Hysteresis 
loss, Neel relaxation and Brownian relaxation41;148. Hysteresis loss is loss of internal 
magnetic energy due magnetisation typical for ferromagnetic materials. Neel 
relaxation arises from the time delay between an alternating magnetic field (AMF) 
and the magnetisation in superparamagnetic particles. This delay can be described by 
a complex magnetic susceptibility with the power loss related to the imaginary part 
of it. Heat generation via Neel relaxation reaches a maximum for SPM particles at a 
particular frequency, which is dependent on particle characteristics such as crystal 
size. Brownian relaxation is heat energy dissipation due to particle rotation and 
collision in the suspension media. This is clearly viscosity dependent and diminishes 
for bound particles. The amount of energy produced by monodisperse SPM in an 
AMF can be described by the specific loss power as41;148 
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    ,             Eq. 2.15 
with    the dc magnetic susceptibility,   the amplitude of the AMF,   its frequency 
and   the relaxation time. The relaxation time is the combination of Neel (  ) and 
Brownian (  ) relaxation times: 
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    ,              Eq. 2.18 
with   the viscosity of the fluid,    the hydrodynamic particle volume,    
Boltzmann’s constant,   absolute temperature,    = 10
-9 s,  the anisotropy constant 
and    the magnetic volume. 
 The specific power loss increases with the frequency of the AMF (until the 
maximum for a particular SPM particle system is reached) and the amplitude of the 
field. However, alternating magnetic fields lead to eddy current induction that can 
lead to unwanted surface heating and peripheral nerve stimulation. Experimental 
studies indicate that the limit for     might be around 5x10
8 Am-1s-1   149. 
 Iron oxide based SPM particles have been used most frequently for magnetic 
hyperthermia150-154 but cobalt based particles155 with higher saturation magnetisation 
and ferromagnetic particles have been used as well. But the toxicity of other 
elements like cobalt might limit their potential applicability156;157.  
 Experimental results particular in animal models of cancer indicate the biggest 
hurdle for its application is the insufficient temperature increase. Major factors 
limiting the local heating capabilities are the amplitude of the AMF, the nature of 
particles, particle concentration, heat dissipation in the tissue and cooling via blood. 
Achieving high particle concentrations is particular difficult if particles are 
administered systemically via intravenous injection. Although preferable from a 
conceptual and practical point of view as it would allow targeting of metastasis 
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elsewhere in the body, non-specific accumulation in organs of the reticular 
endothelial system is a problem even for particles with molecular recognition 
moieties158-160. Direct injection of particles into the centre of a tumour might be 
feasible but it is difficult to achieve a uniform distribution within the tumour. The 
outer rim of the tumour is frequently well vascularised161;162 providing an effective 
heat sink in the regions where tumour stem cells163 may reside. This makes killing 
them particular difficult. Other open questions for the application of magnetic 
hyperthermia for tumour treatment are questions of optimum duration and 
treatment interval164-166.  
 Many researchers acknowledge the limitations of hyperthermia as a single 
treatment strategy for cancer and are hence investigating combination treatments 
with radiation167, chemotherapy168 and others.  
 Magnetic hyperthermia offers other interesting applications in medicine 
particular in the field of controlled drug release. This includes the use for cancer 
therapies but offers options for other therapies as well. Of particular interest for such 
applications are magneto-liposomes85;169;170. Liposomes are spheres made form 
phospholipids with an aqueous or gaseous core whereby the melting temperature of 
the phospholipid membrane is determined via its composition. The core of liposomes 
can be loaded with a drug and magnetic particles. Magnetic particles can also be 
attached to the phospholipid membrane. Molecular recognition elements such as 
antibodies and organic molecules can be attached to the liposome surface to 
increase targeting specificity. Depending on the magnetic moment of these 
liposomes magnetic targeting strategies via the use of magnetic field gradients might 
be used to further increase the concentration of them at the site of interest. After 
the target regions have been reached an AMF can be used to release the drug on 
demand. Magnetic hyperthermia can be used for the controlled release from other 
magneto responsive materials too86;87. 
2.2.4 Magnetic cell tracking  
Cellular therapies offer new therapeutic opportunities. However, to get a 
better understanding of cell based therapies non-invasive imaging methods will be 
needed. This will allow researchers to address questions such as have the cells been 
delivered to the area of interest, are cells migrating to other places, what is the best 
delivery route, do cells functionally integrate into pathological tissues? Potential 
imaging modalities to address these questions are MRI92;103;110;111;171, SPECT172;173, 
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PET174-176 and in the preclinical setting bioluminescence177-179 and near infrared 
imaging180-182.  
Magnetic resonance imaging is particular suitable for cell tracking in the 
context of magnetic cell delivery, as cells are already labelled with magnetic particles 
which allow tracking on MR images. Additional advantages of MR imaging are the 
high soft tissue contrast, the ability to acquire additional information via functional 
imaging and the fact that no radiation is needed. The availability of MRI in clinical and 
preclinical settings allows for transferability of experimental protocols. 
The detection of labelled cells on MR images relies on the change of relaxation 
parameters due to the magnetic moments of labelled cells, in particular a strong 
reduction in the spin-spin relaxation times, T2 and T2*
183-185. A detailed explanation of 
MRI can be found in section 3, while aspects of cell labelling are explained in section 
2.2.2. Furthermore examples for cell MR based cell tracking can be found in chapter 
7. Shortening of T2 and T2* relaxation rates leads to hypointesity on T2 and T2* 
weighted spin- and gradient-echo images. Hence labelled cells appear as dark regions 
on such images. 
 MR imaging has been used in preclinical animal models to track cells injected 
into the myocardium after an infarct over time10;186-188 and to evaluate host graft 
rejection of transplanted organs189-191. These studies showed the feasibility of cell 
tracking without negative effects on cell differentiation88;99;107;108. However, following 
cell delivery, it has been observed that hypointensity losses are slower than the loss 
of injected cells over time. This indicates that iron oxide remains at the site of 
injection after cells have died102;186. There is good evidence that macrophages take up 
magnetic particles from dead cells, which can lead to false positive signals192-194. 
Experimental studies suggested that the differentiation between live and dead 
necrotic cells containing iron oxide might be possible by combining T2 and T2* 
imaging195. Although this might help for certain cases it want be effective if the 
particles are rapidly internalised by macrophages. Tracking of magnetically labelled 
cells has been performed successfully in clinical studies103;110;111 illustrating the 
translation potential. But images have to be analysed with care. 
Magnetic resonance imaging has been frequently employed for cell tracking in 
the brain in pre-clinical and clinical settings43;101;103. MR based cell tracking in the 
brain has proven particular useful as it is currently the only technique which allows 
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long-term tracking. The limitations mentioned above apply for the brain as well. 
Stereotactic injection of labelled cells into the brain leads frequently to local 
haemorrhage formation in the area and along the injection canal101;196;197. This causes 
the formation of iron rich blood breakdown products such as hemosiderin which is 
difficult to distinguish form labelled cells. Nevertheless, magnetic cell tracking in the 
brain is frequently used and allows for the detection of single cells in high field pre-
clinical scanners198. 
The clinical application of MR based magnetic cell tracking has demonstrated 
the safety of this technique as no negative side effects due to cell labelling have been 
reported. Cells seem to tolerate biodegradable iron oxide particles fairly well with 
almost no change in growth and differentiation potential (see section 2.2.2). 
However the major limitations of negative contrast (hypointensity), macrophage 
uptake of free label, label independence of cell status as well as label dilution and 
degradation by growing cells are significant183;185;199. Image hypointensity is 
particularly problematic for cell tracking in regions which show natural hypointensity 
such as tumours, abdominal regions and the lung. New developments in the use of 
ultra fast imaging sequences200-203 as well as susceptibility gradient weighted 
reconstruction204 might bring improvements in these areas. Label independence of 
cell status refers to the fact that MRI cannot be used to distinguish between live and 
dead cells or between differentiated and undifferentiated states. MR sensitive gene 
expression markers such as ferritin205;206, lysine rich proteins207;208 and others209;210 are 
currently under development to address this issue. However, these techniques are 
not compatible with strong magnetic moments in cells. In order to assess the status 
of cells in the context of magnetic cell delivery additional imaging modalities are 
necessary. There are several expression vectors available for SPECT and PET 
imaging211-213 which can be used to gain more information of the cell status. Attempts 
are under way to combine these imaging modalities in order to get high spatial 
resolution and soft tissue contrast from MRI and high specificity and the ability to 
detect molecular expression via SPECT or PET214-216.  
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3 Magnetic resonance imaging  
As indicated in chapters one and two cellular therapies would benefit from an 
increased understanding of the cell behaviour after delivery in vivo. MRI is particular 
suitable for that due to its non-reliance on radioactive tracers, high soft tissue 
contrast, clinical availability and the contrast from iron oxide particles used for 
magnetic delivery. The basic principles of MRI will be outlined in this Chapter. This will 
be followed by mentioning essential components of a magnetic resonance imaging 
system and their functions. Finally, some additional considerations for magnetic 
resonance based cell tracking will be given.  
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3.1 Basic principles 
Magnetic resonance imaging (MRI) is based on the nuclear magnetic resonance 
phenomenon which was discovered in 1946 by Bloch and Purcell. They discovered that 
different atomic nuclei placed in a magnetic field absorb radio frequency (RF) energy at 
different frequencies, their respective resonance frequency.  
MRI exploits quantum mechanical principles of atomic nuclei to generate 
images. Atomic nuclei have an angular moment   given as 
            ,               Eq. 2.19 
where   is the spin of the nucleus. Nuclei with an odd number of protons or an even 
number of protons but an odd number of neutrons have a net magnetic moment:  
           ,                Eq. 2.20 
with   the gyromagentic ratio, a constant for a particular nuclei. Nuclei which do not 
have a net magnetic moment cannot be observed with MRI. Hydrogen has a high 
abundance in biological tissues and a high gyromagnetic ratio which makes it the 
primary nuclei observed in MRI. Protons undergo a Zeeman splitting into two energy 
levels when placed into a magnetic field B0, with an energy difference of  
               .               Eq. 2.21 
The two energy levels are aligned parallel or anti-parallel to the main field B0 with 
populations of protons  following a Boltzmann distribution: 
           
 
  
       ,              Eq. 2.22 
with    the Boltzmann constant and the absolute temperature  . 
The excitation of a proton from the low to the high energy state requires photons with 
the energy of    (see Eq. 2.21), at a particular frequency, the Larmor frequency: 
       
   
  
    .               Eq. 2.23 
The magnetic moment of a proton ensemble can be described in classical terms. The 
nuclear magnetisation of the protons ( ) placed in a magnetic field is experiencing a 
torque (Eq. 2.11) and start to precess around B0 at the Larmor frequency following  
    
  
  
         .              Eq. 2.24 
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For an ensemble of protons at equilibrium, the difference between parallel and 
anti-parallel aligned protons is small. However, the application of a magnetic field 
perpendicular to B0 oscillating at the Larmor frequency rotates the magnetisation 
vector of the assembly into the X-Y plane. In MRI systems the Z axis is aligned with B0 
(see Figure 2). The precession of the magnetisation in the X-Y plane can be detected 
via the induced current in a coil tuned to the Larmor frequency, the receiver coil. Once 
the magnetisation has been tilted away from the equilibrium i.e. by 90 degree into the 
X-Y plane, it will return to the equilibrium via the spin-lattice relaxation. The spin-
lattice relaxation is the recovery of the Z component of the magnetisation vector as 
the system returns to reach its original magnetisation (  ) given by 
       ( )    (     (
  
  
))    ,             Eq. 2.25 
with    the spin-lattice relaxation time (This follows from the Bloch equations for a 90 
degree RF pulse). 
As the magnetic moment is tipped into the X-Y plane it will rotate around Z at the 
Larmor frequency. It is hence convenient to define a reference coordinate system (X’-
Y’-Z) which rotates at the Larmor frequency around Z. In the X’-Y’-Z coordinate system, 
the transverse magnetisation is decaying from its maximum (   , for a perfect 90 
degree excitation) to zero. The transverse relaxation time T2 specifies the mono-
exponential decay of transverse magnetisation: 
         ( )       (
  
  
)    .             Eq. 2.26 
T2 decay is caused by magnetic interactions between spins which leads to loss of phase 
coherence. However, inhomogeneities in the B0 field lead to increased decay rates. For 
gradient echo, the observed relaxation rate (T2*) can be described as the combination 
of relaxation due to both non-recoverable (T2) spin-spin and recoverable relaxation 
due to field inhomogeneities (T2i): 
    
 
  
  
 
  
 
 
   
   ,               Eq. 2.27 
MRI exploits inherent relaxation time differences as well as differences in 
proton densities to generate image contrast. This is achieved by the use of different 
imaging sequences. Imaging sequences are timing protocols for the application of 
magnetic field gradients, RF pulses and signal recording.  
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Spatial localisation of MR signals is necessary to generate an image. The 
imaging technique MRI which allows that was developed independently by Mansfield 
and Lauterbur in 1973. This is achieved via slice selection, frequency encoding and 
phase encoding. As mentioned above the excitation of spins requires the application of 
an RF pulse at the Larmor frequency. The Larmor frequency is linearly dependent on 
the magnetic field strength. A combination of a particular shaped RF pulse (e.g. sinc or 
gaussian) with a linear field gradient can be used to limit the excitation of spins to a 
thin slab. Frequency and phase encoding are used for the spatial localisation of the 
signal to a single voxel of this slab. If a linear magnetic field gradient is applied at the 
time of the signal acquisition (during readout) along one axis, excited spins will possess 
a linear frequency dependence along that axis. For the orthogonal axis phase encoding 
is used. For that, a linear field gradient is applied before the readout starts. This leads 
to a phase difference in the rotating spins which is dependent on their position along 
the axis of the applied phase-encode gradient. The process is repeated with varying 
gradient strengths (or moments) in order to fill up a raw data matrix (in time-domain), 
known as k-space. Once the matrix has been filled a Fourier transformation (FT) can be 
performed to generate an image (frequency domain data). 
The two simplest imaging sequences for MRI are the gradient echo and the 
spin echo sequence. Sequence diagrams for both of these imaging sequences are 
shown in Figure 1. 
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Figure 1 Spin echo and gradient echo imaging sequence. The first row gives a 
simplified graphical representation of the magnetisation vector (M) during the spin 
echo sequence in a rotating reference coordinate system. Appling a 90° RF pulse 
rotates the magnetisation vector into the transverse plane (X’-Y’ plane) (1). After 
that, de-phasing of the magnetisation vector starts (2). The 180° pulse rotates the M-
vector around (y normally) the x-axis (3). This reverses the de-phasing direction (4) 
and causes the echo to build up via re-phasing (5). T1 decay would normally decrease 
the tip angle and bring the M-vector towards the z axis. This has been neglected for 
the images 1-9. The row below the pulse sequences shows effects of the gradient 
echo sequence on the M-vector. A RF pulse < 90° is applied (6). This tips the M-vector 
accordingly towards the X’-Y’ plane. The phase encoding gradient is applied together 
with a reversed frequency encode gradient to induce de-phasing in the X’-Y’ plane 
(7). Switching of the FE gradient into the opposite direction induces re-phasing (8) 
and hence induces the gradient echo signal (9) when the M-vector regains 
coherence. M: magnetisation vector, B1: applied field induced by RF pulse, RF: radio 
frequency, SS: slice selection, PE: phase encoding, FE: frequency encoding, S: signal, 
TE: time until echo, TR: repetition time. 
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A pulse sequence diagram for a spin echo sequence is displayed on the left 
side of Figure 1 with a depiction of the magnetisation vector of a voxel in the top row. 
This depiction corresponds to an axial slice where SS=Z, PE=X and FE=Y. For simplicity 
reasons T1 decay has been neglected in Figure 1. A 90° RF pulse is applied at the same 
time as the slice section gradient (SS) to excite an imaging slab. This rotates the 
magnetisation vector into the X’-Y’ plane. Following slice selection, a phase encoding 
gradient is applied along the phase encode direction (PE). During that an additional 
gradient is applied along the frequency encode direction (FE) which de-phases spins 
aligning the start of the echo with edge of k-space. After de-phasing due to T2 decay 
has occurred for half of the echo time (TE/2), a slice selective 180° RF pulse is applied 
together with a slice selection gradient to refocus the spins (e.g. flip the magnetisation 
along the X axis). This causes the spins to re-phase and to generate the spin echo. A 
frequency encode gradient is applied during the acquisition of the echo. The time 
needed for the execution of all of these steps, the time between two excitations is the 
repletion time TR. PE gradients are applied in a stepped fashion increasing from minus 
PE max to plus PE max with one PE step for each line of k-space. A spin echo sequence 
will lead to signal intensity   for one voxel following: 
         (   
 
  
  )  
 
  
     ,             Eq. 2.28 
with a field strength and nuclei specific constant   and the density of the imaged 
nuclei, i.e. proton density   . The product of these two constants is proportional to   
in equations 2.24 and 2.25. 
A gradient echo sequence diagram is shown on the right side of Figure 1 with a 
depiction of the magnetisation vector for one imaging voxel below. A slice selective RF 
pulse is applied together with a slice selection gradient. This tilts the magnetisation 
vector away from Z into the X’-Y’ plane. The angle between Z and M is called the flip 
angle which is typically < 90°. A negative lob of the SS gradient is used to re-phase 
spins which were de-phased during slice section. Phase encoding is performed along 
one of the two remaining axis via the application of a phase encode gradient. As 
mentioned above phase encode gradients are increased stepwise at each TR for each 
k-space line. A gradient echo is generated after the application of a positive gradient 
which causes re-phasing of spins. This gradient echo occurs when the positive gradient 
moment (gradient amplitude * application time) is equal to the negative moment. The 
signal equation for gradient echo sequences is similar to the spin echo equation with 
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two differences: T2* replaces T2 as de-phasing due to field inhomogeneities are not re-
phased (see equation 2.26) and typically a less than 90° flip angle will be used   : 
          (      
 
  
  
 
) 
(   
 
  
  )
(        
 
  
  )
   .            Eq. 2.29 
 Image contrast on spin echo images can be influenced via the appropriate 
selection of TR and TE. For gradient echo images suitable TR, TE and flip angles need to 
be selected. However, if this intrinsic contrast is insufficient contrast agents can be 
used. Contrast agents are classified as T1 or T2/T2* contrast agent depending on the 
relaxation mechanism they primarily influence. The most frequently used T1 contrast 
agents are the paramagnetic ions gadolinium and manganese. They reduce spin-lattice 
relaxation times via chemical exchange between water molecules surrounding the ion 
and bulk water molecules. Superparamagnetic iron oxide particles (SPION) are the 
main T2/T2* contrast agents. The spin-spin relaxation time is reduced due to the 
magnetic field inhomogeneities produced by SPION. 
3.2 Basic components of an MRI scanner 
Modern MRI scanners consist of a superconducting magnet in a cryostat, 
gradient coils, radio frequency transmitter and receiver and a computer. These 
components are illustrated below. The function of individual components will be 
explained briefly in the following section. 
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Figure 2: Schematic of an MRI scanner. The superconducting magnet and permanent 
shims are indicated by the outer cylinder. Gradient coils consist of two Golay coils for 
X and Y gradients and a Maxwell pair for Z gradients. Resistive shim coils are not 
drawn on the picture although their shim power supply unit (PSU) and control is 
indicated. A host computer provides an interface to prepare imaging sequences. 
Commands are sent via the communications processor to subunits. The gradient 
controller produces a gradient waveform which is amplified by gradient amplifiers. 
The frequency unit produces radio frequency waveforms which are amplified by the 
RF amplifier. An RF coil picks up induced currents from exited spins in the specimen 
(red sphere) which are amplified by the Preamps and digitised in the Receiver unit. 
The timing processer ensures accurate timing and synchronisation of all sub systems. 
Following the standard convention the positive Z axis points to the front of the 
scanner (right side of the image) with B0 parallel to Z. T/R: transmit/receive, 
commun.: communication 
The purpose of the magnet is to provide a very homogeneous magnetic field 
to align the sample spins (spins in the context of MRI refer to proton spins of imaging 
nuclei, mainly hydrogen). As outlined in the previous chapter the precession 
frequency, the Larmor frequency is dependent on the magnetic field strength. This 
sets high uniformity requirements for the magnet (< 5 ppm). Typical field strengths of 
modern superconducting MRI magnets are 1.5-3 T clinically up to 9.4 T for research 
systems and up to 21 T for preclinical scanners. These superconductors (NbTi) are 
maintained in liquid Helium in a cryostat. 
Gradient coils are resistive coils in the bore of the main magnet which 
generate linear magnetic field gradients over a central spherical space, the imaging 
sphere. A Maxwell pair is used to generate a liner gradient along the Z axis while Golay 
coils are used for linear gradients along X and Y. Golay coils for X are rotated by 90 
degrees around Z with respect to Y. 
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A radio frequency coil is placed in the centre of the gradient coils and main 
magnet. Specimens are placed in the centre of volume coils as shown in Figure 2 or 
next to surface coils. RF coils are used for two purposes; first to transmit a RF wave to 
generate a rotating B1 field and secondly to pick up induced currents from excited 
spins (the rotation of their nuclear magnetic moment in the X-Y plane).  
Additional electronic components are needed for the control of an MRI 
scanner. A host computer is used as a user interface to select a particular imaging 
sequence and set imaging parameters. Appropriate commands are sent to subsystems 
via the communications processor. For example at the start of an imaging session the 
shim controller is used to set currents for active shim coils which are produced by the 
shim power supply unit (PSU). The execution of an imaging sequence typically requires 
the application of a particular RF wave and controlled field gradients. RF waves 
produced in the RF waveform generator (RF frequency unit) are amplified by the RF 
amplifier and sent to the RF coil via a transmit/receive switch. Gradient commands 
from the communications processor will be translated into particular gradient 
waveform, amplified and applied to the gradient coils. A certain time after the 
application of the RF excitation, the induced current in the RF coil will be amplified by 
the RF pre-amplifier and converted into a digital signal in the receiver unit. All of the 
above steps have to be performed at precise time points which are controlled via the 
timing processor. Digital time domain data is sent to an image processor which 
performs a Fourier transformation to generate an image. 
3.3 Magnetic resonance imaging in the context of magnetic particles 
The use of MRI for cell tracking has been discussed in section 2.2.4 this section 
will hence only briefly discuss the use of superparamagnetic iron oxide particles 
(SPION) as a T2/T2* contrast agent for other application. 
The FDA approved the use of SPION for the detection of liver or spleen 
metastasis, magnetic resonance angiography and perfusion imaging217. However, the 
production of these contrast agents has been discontinued as they did not prove 
economically viable. There are new contrast agents currently in clinical trials aiming for 
the above mentioned applications (Supravist, Schering AG, Germany; Combidex, 
Advanced Magnetics Inc, MA).  
Although there are interesting applications for these ferrofluids, the 
development of targeted contrast agents (molecular recognition) will open a new 
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range of applications. Preclinical studies have shown the potential of antibody 
conjugated SPION for cancer staging218;219, assessment of inflammation in the 
brain220;221, organ rejection189;190, atherosclerotic plaque staging222;223 and others. These 
contrast agents or molecular imaging agents will extend the MRI applications of SPION. 
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4 Delivery of magnetically labelled cells using an MRI scanner 
As outlined in chapter two, magnetic targeting applications can be classified 
depending on the origin of the magnetic field gradient used leading to three major 
groups: permanent magnets, electromagnets and flux concentrators. An MRI scanner 
is essentially an arrangement of different electromagnets with amplifies and control 
modules. This chapter focuses on attempts to use the gradient coils of an MRI scanner 
for the steering of magnetically labelled cells. 
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4.1 Introduction 
The success of cell therapies depends partially on the ability to deliver the cells 
to the site of injury. Targeted magnetic cell delivery is an emergent technique for 
localised cell transplantation therapy. The use of permanent magnets limits such a 
treatment to organs close to the body surface or an implanted magnetic source113;117-
119;146;224;225. One method which has recently attracted attention is the use of magnetic 
resonance imaging (MRI) systems to steer ferromagnetic objects deep inside the 
body128-130;226.  
This is particularly appealing due to the high magnetic field strength, and the 
precise spatial and temporal control over magnetic field gradients provided by an MRI 
system. Combining this functionality with the conventional MRI use to generate high 
contrast soft tissue images may allow for interactive real time feedback for the spatial 
position of the cells, or at least immediate confirmation of targeting success, as these 
cells appear hypointense or dark on MR images. Although the use of a magnetic 
resonance system for targeting has been investigated for ferrofluids128 and micro-
particle delivery129;130, it has not been attempted in the context of cell delivery.  
The aim of this study was to investigate the feasibility of using a magnetic 
resonance scanner for targeting (MRT) to guide cells within a bifurcating vascular 
system. In particular, single bifurcation targeting efficiency was estimated, as this 
could be applied in a consecutive fashion at several branches directing a bolus of cells 
to a small region within the vascular network. In addition, the feasibility of an MRI 
system to visualise the effect of the targeting gradients on the cell distribution was 
investigated, as this would enable visualisation of cell distribution or the possible 
implementation of interactive control. 
 
The hypotheses for these experiments were: 
 MRI gradient coils can be used to steer magnetically labelled cells in a flow 
phantom. 
 The difference in cell distribution due to magnetic steering can be 
detected via MRI. 
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4.2 Materials and Methods 
4.2.1 Cell culture and cell labelling 
Human mononuclear cells (MNCs) were collected by leukapheresis from 
peripheral blood of G-CSF-stimulated donors following the protocol approved by the 
department of health and the UCL ethics committee. Cells were washed twice with 
phosphate buffered saline (PBS), centrifuged for 10 min at 400 g, plated in Dulbecco's 
Modified Eagle Medium (DMEM) (Gibco, UK) and incubated at 37 °C and 5% CO2 for 2 
hours. After two hours non-adherent cells were washed away and the media 
replaced with fresh DMEM + 10% fetal bovine serum (FBS) (Invitrogen, UK). 
Mesenchymal stem cells were obtained from Tulane University, New Orleans, USA, 
and cultivated in α-MEM supplemented with 16% FBS (all Invitrogen, UK) at 37 °C and 
5% CO2. 
Labelling experiments were conducted when 80% confluence was reached. 
For MNC labelling either 45 μL Endorem, or 50 µL BioMag solution (particles washed 
3 times with fresh media) or 5 µL fluidMAG were added per mL culture media, and 
cells were cultivated for 24 h. Cells were detached with Trypsin-EDTA (0.25% in 
Hank's Buffered Salt Solution HBSS, Sigma Aldrich Ltd., England) and washed 3 times 
with PBS. Cell concentrations were estimated with a haemocytometer. MSCs were 
labelled for 24 hours by adding 5 µL fluidMAG solution per mL medium. After that 
cells were detached with Trypsin-EDTA and washed 6 times with PBS. MNCs and 
MSCs were re-suspended to 3x106 cells per ml in PBS containing 5% serum for 
targeting experiments. Cell viability after labelling was assessed via trypan blue 
exclusion (Invitrogen, UK). 
4.2.2 Cell viability 
For the cell viability assay, 5000 MNCs were seeded per well into a 96-well 
plate. The plate was incubated at 37 °C and 5% CO2 . After two hours, media was 
replaced with fresh media containing varying amounts of the different SPION and 
incubated for 24 hours. The media was removed, the cells were washed once with 
200 µL media per well, 200 µL fresh media + 20 μL MTS tetrazolium compound 
solution (CellTiter 96® Non-Radioactive Cell Proliferation Assay, Promega, UK) were 
added. Following 4 hours incubation the absorption for each well at 490 nm and 690 
nm was measured with a micro-plate reader (Tecan, Switzerland). Three wells were 
measured for each concentration per plate with three replications for the plate. 
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4.2.3 Quantification of cell labelling 
A series of dilutions of Endorem, fluidMAG and BioMag particles in water was 
prepared (120, 60, 30, 15, 7.5, 3.75, 1.88, 0.94 µg iron per mL). For each 
concentration, two 250 μL tubes (Eppendorf, Germany) were filled with 120 μL of 
diluted particle suspension and 120 µL of 2% low melting point agarose (Sigma-
Aldrich, UK). These tubes were submerged in Fomblin perfluoropolyether PFPE 
(Solvay Solexis, Italy). Imaging was performed using a 9.4T VNMRS horizontal bore 
scanner (Varian Inc., Palo Alto, CA) with a shielded gradient system (400 mT/m). A 
series of T2-weighted images was acquired with a spin-echo sequence and the 
following parameters: TE 4.5-110 ms (18 steps exponentially distributed), TR 10 s, 
FOV 60x40 mm, slice thickness 1 mm, matrix 512x256.  
Labelled cells were counted with a haemocytometer and diluted to 1x106, 
5x105, 1x105, 5x104 and 1x104 cells per mL in PBS. For each concentration, two 250 μL 
tubes were filled with 120 μL of diluted cell suspension and 120 µL of 2% low melting 
point agarose. T2-weighted images were acquired using the same parameters as 
above. 
The mean segmented signal intensity value was fitted to the spin echo signal 
equation (Eq. 2.28) using Matlab (MathWorks, Natick, MA) to estimate their T2 
values. A linear regression for 1/T2 (R2) versus iron concentration was performed for 
the dilution series using the R software. 
4.2.4 MRT of cells 
A custom vascular bifurcation model was designed and manufactured from 
polycarbonate (AG prototypes, UK ). The phantom consists of a cylindrical pipe with 
an internal diameter of 0.8mm and a 30 bifurcation (see Figure 3). The phantom was 
connected to an infusion pump (PHP2000 Harvard Instruments, UK) and placed into 
the centre of a 9.4 T MRI scanner (VNMRS, Varian Inc. Palo Alto, CA) equipped with a 
60 mm bore size gradient set (rise time 5 T m-1 ms-1, max. gradient strength 1 T/m).  
The flow direction of the phantom was parallel to B0 (Z). Cell suspension 
samples (0.8 mL of 3x106 cells/mL) were infused at flow rates of 0.06 mL/min to 1.8 
mL/min, leading to a mean velocity of 0.2 cm/s to 6 cm/s assuming parabolic laminar 
flow. During the infusion, gradients (amplitude + or -500 mT/m) were applied in the X 
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direction, perpendicular to the direction of flow. Due to hardware limitations the 
gradients were pulsed (2 ms on, 7 ms off using max. slew rate).  
Cell suspensions leaving each bifurcation outlet tube (volume 0.4 mL each) 
were collected and cell concentrations were estimated using a haemocytometer. This 
was repeated three times for each gradient direction, labelling type and flow 
velocity.  
In order to visualise the cell distribution with MRI, the flow was stopped and 
gradient echo images were acquired using a 3 cm surface coil (Varian Inc. Palo Alto, 
CA) with the following parameters; TE 1.24 ms, TR 100 ms, FA 30, field of view 50x30 
mm, matrix 192x128, NSA 50. 
  A      B 
 
 
 
Figure 3: (A) Schematic drawing of the vascular bifurcation phantom: The tube 
diameter for this bifurcation is 0.8mm and the bifurcation angle 30. The Z axis of 
the phantom is aligned with B0 of the scanner. (B) shows the separation segment 
outlined in (A) with schematic representations of the flow profile and cells 
containing superparamagnetic iron oxide particles. The succession of a cell (shears) 
with internalised iron oxide particles (black dots) is a representation of the 
movement as one is attracted to the positive X axis due to the magnetic force 
acting on them. 
 
4.3 Results 
Figure 4 demonstrates the effect of incubation with different iron oxide 
concentrations on MNC viability for a 24 hour labelling period. No significant 
differences were found for the effect of Endorem and fluidMAG on cell viability, which 
reflects their comparable characteristics (diameter: 80-150 nm vs. 200 nm, dextran vs. 
starch coating). However, the labelling with BioMag particles resulted in a statistically 
significant decline in cell viability. This is most likely attributable to the size of these 
particles (diameter: 1.5 µm). For the purpose of this study, iron oxide concentrations 
that preserved at least 90% cell viability (Figure 4) were selected, as a compromise 
between iron labelling and number of available viable cells. 
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Figure 4: Effect of concentration of iron oxide in the culture media on cell viability. 
Nominal particle diameter for the super paramagnetic iron oxide particles are: 
Endorem 80-150 nm, fluidMAG NC/D 200 nm, BioMag 1.5 µm. Viability on the y-axis 
refers to metabolic activity normalised to unlabelled control cells. Diamond, squares, 
triangles: mean ± standard deviation (n=3x3 for each data point) 
 
Iron oxide particles cause a signal loss on an MRI image that is dependent on 
the iron concentration and imaging parameters (see section 3.1). In order to estimate 
the internalised iron concentration a dilution series for each particle type and 
estimated MRI R2 values (see Figure 5D). All three particle types showed a strongly 
linear correspondence to R2 (R
2 0.993 - 0.998). Using these relationships, the amount 
of internalised iron for labelled MNCs was estimated to be 14 ± 7 pg/cell for Endorem, 
68 ± 5 pg/cell for fluidMAG, and 292 ± 17 pg/cell for BioMag. In addition we have 
assessed fluidMAG labelled MSCs (225 ± 30 pg/cell), as these cells have recently been 
suggested as a possible lung cancer therapy. 
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Figure 5: Example images of the T2 phantom, containing 18 Eppendorf tubes with 
different concentrations of iron oxide, randomly distributed in the phantom. 
Different iron concentrations led to signal intensities which are exponentially 
dependent on the echo time of the MRI sequence. Echo times are: 7.2 ms (A), 25 ms 
(B) and 84 ms (C). A series of such images is the basis for the linear regression. An 
example for such a regression of R2 versus particle concentration for BioMag 
particles is shown in (D) (adjusted R2 0.998). 
 
To investigate the feasibility of MRT of cells, a small artery flow phantom was 
placed into the centre of our MRI system and connected to an infusion pump. A 
positive or negative magnetic field gradient (± 0.5 T/m) was applied along the X axis 
(see Figure 6), while cell suspensions were infused through the bifurcation. Figure 6 
displays the targeting of cells labelled with BioMag particles at 1cm/s fluid velocity. 
With these settings, 75% of all cells were directed into one branch of the vascular 
bifurcation model. Furthermore, a positive and negative field gradient attracted the 
cells toward the left or right branch respectively. The term ‘targeting efficiency’ for this 
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and the next chapter is defined as the percentage of cells removed from exit tube A to 
exit tube B, where B is the targeted exit tube. In the aforementioned example the 
targeting efficiency was thus 50%.  
 The targeting efficiency of cell suspensions labelled with the three different 
iron oxide particles was investigated for a range of flow rates (0.2 – 6 cm/s, see Figure 
7). Increased flow rates led to a decrease in targeting efficiency (e.g. MNCs labelled 
with BioMag; targeting efficiency 49%, 31%, 13%, 0.5% for 1, 2, 4 and 6 cm/s fluid 
velocity, respectively) as the magnetic force had less time to deflect cells before they 
reached the bifurcation point. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: (A) and (B) show the cell concentrations at the exit tubes following 
application of positive (A) and negative (B) X gradients for cells labelled with BioMag 
particles at a flow rate of 1 cm/s. Gradient echo images show a reduced signal 
intensity in the exit branch to which the cells where directed (red arrow) (TE 1.24 ms, 
TR 100 ms, FA 30, FOV 50x30 mm, matrix 192x128, NSA 50). 
 
 However, increasing the targeting efficiency beyond 50% proved difficult, as 
further reductions of the flow rate caused substantial agglomeration of cells at the 
bifurcation point of the phantom. This is illustrated in Figure 7 which shows that the 
A 
B 
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targeting efficiency for a given flow rate and illustrates its correlation with the amount 
of internalised iron oxide as equation 2.12 predicts. No statistically significant 
difference was found for the targeting efficiencies for MNCs labelled with BioMag and 
MSCs labelled with fluidMAG, which was expected as the amount of internalised iron 
was in a similar range (fluidMAG 225 ± 30 pg/cell and BioMag 292 ± 17 pg/cell). 
 
 
 
 
 
 
 
 
 
Figure 7: Targeting efficiency for human mononuclear cells (hMNCs) labelled either 
with Endorem (red triangles) or BioMag particles (blue diamonds) for different flow 
rates. The green circles show the targeting efficiency for MSCs labelled with 
fluidMAG particles. Each point on the graph corresponds to the average targeting 
efficiency for three experiments targeting the right and three experiments targeting 
the left tube (n=6). The lines connecting the markers are only for illustration 
purposes. 
 
 As previously mentioned, iron oxide particles cause a signal loss in T2
* 
weighted MRI images. It was therefore investigated if the labelled cells could be 
visualised to monitor the cell distribution following MRT. Figure 6 demonstrates that 
deflected cells could be visualised as a reduction in signal intensity, which is due to the 
increase of iron oxide per unit volume. 
 Theoretical predictions of targeting efficiency based on Eq. 2.12 were always 
lower than experimental results. This is most likely due to iron oxide dipole-dipole 
interactions leading to cell aggregation, which have not been included in this 
calculation, but are likely to play a role during targeting. The importance of these 
interactions will be further investigated in chapter 5. 
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4.4 Discussion 
Different types of commercially available SPION together with two different 
cell types, which have been previously utilised for cardiac and vascular repair227-229 
were tested for this study. Acceptable SPION labelling concentrations were selected 
upon their impact on cell viability while their internalisation was estimated via T2 
relaxometry. Endorem and fluidMAG labelling concentrations used in this study are 
comparable to others46;100;108;230;231. Particle internalisation based on this labelling 
concentrations was in good agreement with previously reported values 44;117;231. From a 
magnetic targeting perspective, high iron content per cell is desirable as the magnetic 
force scales linearly with the amount of internalised iron oxide (see equation 2.12). 
However, it is clear that high particle concentrations in the culture media can reduce 
cell viability (see Figure 4) and optimisation of cell labelling (high cellular iron content 
without loss of cell integrity) is likely to be necessary for each application117. Finally, we 
observed that labelling MNCs with BioMag particles leads to a marked uptake of iron 
oxide, which we hypothesise would be favourable for cell targeting. 
Targeting efficiencies of up to 50% were observed for low to modest flow 
rates. These efficiencies indicate that without further modification in terms of 
increased gradient strength or methods to enhance aggregation temporarily, potential 
in vivo applications would be limited to peripheral vessels with low flow rates. 
Additionally a temporary reduction of flow rates during delivery might be possible as 
previously used for the steering of a steel ball in a carotid artery129. Our phantom used 
linear flow while in vivo applications would be exposed to pulsatile non-linear flow 
profiles. This would reduce the targeting efficiency comparable to the averaged mean 
flow rate with further reduced for cell path changes due to turbulences. However, the 
diameter of our phantom is characteristic for small peripheral arteries where the 
amplitude of the pulsatile flow is already substantially reduced. Effects due to the non-
Newtonian characteristics of blood should be small for the selected diameter. The 
separation distance used for our phantom is longer than expected for an in vivo 
application and would lead a reduction in targeting efficiency directly proportional to 
the separation length. Any in vivo application is likely to involve more than one 
bifurcation which would lead to logistic reduction in targeting efficiency dependent on 
the number of bifurcations through which the cells need to be steered. The potential 
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scalability of such a system will be discussed in the next chapter together with the 
parameters of a theoretical model. 
Internalisation of large amounts of SPION is not only useful for targeting but 
obviously equally useful for cell tracking with MRI as it increases the magnetic 
susceptibility variations. This allows for cell tracking via MRI and potentially for a 
feedback control. However, a closed control loop might be difficult to achieve as the 
time window for the detection of cells would be very short (ms range). 
The discrepancy between calculated and observed targeting efficiency 
indicates that cell aggregation is likely to take place and allows for more efficient 
targeting. This aggregation is likely to be mediated via dipole-dipole interactions 
whose importance has been demonstrated previously128;232;233. 
 
4.5 Conclusions 
This study demonstrated the feasibility of cell targeting using an MRI scanner. 
In particular it showed that live human cells can be labelled with different SPION and 
targeted within a vascular bifurcation model using the magnetic field gradients of an 
MRI scanner. Depending on the amount of internalised iron oxide particles, targeting 
efficiencies of up to 50% could be achieved for modest flow rates.  
In addition to that, this study showed that imaging of cell distributions 
following MRT is feasible, indicating the possibility for real-time image-guided 
targeting using an MRI system. 
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5 An analytical model for cell delivery in an MRI scanner 
The experimental results shown in chapter 4 indicate that targeting efficiency 
for cell steering in a flow phantom with MRI gradients is strongly influenced by cell 
aggregation. This chapter aims to develop a simplified analytical model to predict 
targeting efficiencies and compare these predictions with experimental results. In 
order to validate the assumption of aggregation due to dipole-dipole interactions a 
confocal endoscope was used to image cell behaviour inside of the MRI scanner. 
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5.1 Introduction 
This study investigates an important aspect of the magnetically assisted 
delivery process itself, namely the ability to understand and predict the direction of 
motion of magnetically labelled cells in the vasculature. For that a simple analytical 
model describing magnetic cell steering in an MRI scanner was derived. Some practical 
simplifications were introduced to assist in the cell tracking and steering process, 
including a weighting factor to account for both the cell distribution in a tube that is 
projected into a 2D plane, and the presence of prolate spheroids to account for cell 
aggregation. This model was compared against experimental results which highlighted 
the importance of cell aggregation at lower flow rates. In order to confirm these 
predictions we used confocal endoscopic imaging inside and outside of an MRI scanner 
to visualise cell distribution and aggregation. 
 
The hypotheses for these experiments were: 
 A simplified analytical model can be used to describe the cell steering 
efficiency for a flow phantom in an MRI scanner. 
 Cell aggregation due to dipole-dipole interaction is a major factor leading 
to increased targeting efficiency. 
 Cell aggregation can be confirmed experimentally via confocal endoscopy. 
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5.2 Materials and Methods 
5.2.1 Theoretical model 
The main driving force for cell movement inside of the MRI scanner is the field 
gradient produced by the coils used to generate the imaging gradients. The magnetic 
field  can be described using Maxwell’s equations (see 2.1.1):  
          , and                  Eq. 5.1 
            
  
  
                     Eq. 5.2 
where μ  and    are the magnetic and electric permeabilities of free space,   the 
electric field and   the current density. The bore of an MRI scanner is a source free 
field which means that there are no electric fields or currents present. Accordingly 
equation 5.2 reduced to: 
          .                  Eq. 5.3 
Equations 1 and 3 can be rewritten in their component forms as: 
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                 Eq. 5.5c 
Equations 5.4 and 5.5 contain five independent derivatives. The first three of them 
can be selected as the linear field gradients which are derivatives of    as the main 
field is orientated along the z-axis in MR systems: 
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 .               Eq. 5.6 
For a symmetrical z gradient (  ) in a cylindrical coordinate system        and 
       should be identical. We can therefore introduce a symmetry parameter α: 
   α   
      
  
;    α   
      
  
 .               Eq. 5.7 
As the last independent variable we can chose equation 5.5c: 
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 .                   Eq.5.8 
All the partial derivatives described in Equations 5.4 and 5.5 can be expressed with 
the independent variables described in Equations 5.6, 5.7 and 5.8. The field produced 
by the gradient coils can then be expressed as: 
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For MRI gradient coils     and due to the cylindrical geometry α     . Equation 
5.9 can therefore be simplified to: 
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]  ,             Eq. 5.10 
which is an especially convenient algebraic expression for the magnetic field in MRI 
systems 234, as it is common practice for scanner manufacturers to supply data on   , 
  , and    amongst the specifications of their instruments (for field maps see Figure 
8).  
In addition Equation 5.10 shows explicitly that gradients along the x- and y-
axes are produced by the    field. Hence we can have a magnetic force along those 
axes despite the magnetisation of material introduced into the field of the scanner 
being solely along the z-axis. 
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Figure 8: A shows a schematic drawing of the separation area of the vascular flow 
phantom. An aggregate of magnetically labelled cells is symbolised by grey circles 
and their path over time by the fading copies of this aggregate assuming a positive 
X gradient. A grey circle with a dashed line indicates the field of view of the 
confocal endoscope. B0: orientation of the magnetic field in the MRI scanner, Fm: 
magnetic force, FD: fluid drag force, RC: radius of cells, Rt: radius of tube, vf: fluid 
velocity, a: equatorial radius of prolate spheroid as a model for aggregated cells, c: 
polar radius of prolate spheroid. B shows three dimensional plots for the magnetic 
field components (Bx, By, Bz) in the MRI scanner without a magnetic field gradient 
while C shows plots for the magnetic field components in the MRI scanner with a 
field gradient of 500mT/m applied along the x-axis. (The same coordinate system as 
used for the model is used for the field plots.  
The magnetic force acting on a particle is dependent on its magnetic susceptibility, 
the field strength and the gradients of the field, which can be expressed as: 
       (   )  , and              Eq. 5.11 
      
    
  
                Eq. 5.12 
where   is the particle volume and    is the magnetic susceptibility difference 
between the particle and its surrounding fluid.  
This equation can be simplified for the case of magnetic resonance targeting 
(MRT) of cells since the magnetic particles will be fully magnetised due to the strong 
   field of the scanner. We can therefore simplify equations 5.11 and 5.12 to: 
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         (    )               Eq. 5.13 
where  is the number of magnetic particles in a cell and   is the saturation 
magnetisation for a magnetic particle. As the magnetisation of particles in an MRI 
scanner is mainly along the z-axis, the x and y magnetisation components can be 
neglected reducing Eq. 5.13 to: 
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           Eq. 5.14 
For our experiments only gradients across the x-axis were used (  ). We can 
therefore reduce our mathematical model to two dimensions and simplify Eq. 14. An 
additional scalar needs to be added to account for the fact that imaging gradients can 
only be switched on for short times at high amplitudes and are therefore operated in 
an on/off fashion, referred to as the systems duty cycle (  ). Using that and 
Equations 5b we can write the magnetic force along the x-direction as: 
               
   
  
 .             E.q. 5.15 
The magnetic force is opposed by the drag force of the fluid which can be stated as 
Stokes drag force for low Reynolds numbers: 
             (     ) ,            E.q. 5.16 
where    is the cell radius,   the dynamic viscosity and       is the difference 
between the cell velocity and the fluid velocity.  
Cells are likely to aggregate in chain like structures. We can introduce a form 
factor   to extend Stokes drag to non spherical objects
235:  
             (     )   , and           E.q. 5.17 
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] .             E.q. 5.18 
where    is the diameter of a sphere with the same projected area as the area of the 
object projected normal to its direction of motion while    is the diameter of a 
sphere with the same total surface area as the object. For a prolate spheroid 
Equation 5.18 can be written as: 
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 ,           E.q. 5.19 
where   is the equatorial radius and   the polar radius of a prolate spheroid (a<c) as 
shown in Figure 1. 
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We can use Eq. 5.17 to investigate the effect of cells arranged to prolate spheroids 
with different diameter to length ratios    on targeting efficiency: 
       
 
 
  .              E.q. 5.20 
As the flow rates used for our experiments are all in the laminar flow region, 
the inflow profile can be described as: 
      ( )     ̅̅ ̅ [  (
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] ,            E.q. 5.21 
with    as the tube radius and   ̅̅ ̅  the average fluid velocity in the tube. The 
trajectory of cells can be calculated by equating the magnetic and the drag force (see 
Figure 8). Note that as our model does not include inertial forces, the cells will 
immediately travel at the maximum velocity determined by the magnetic and drag 
forces 
           .              E.q. 5.22 
 The cell velocity in the z-direction is determined by the fluid velocity, as there 
is no magnetic force acting in the z-direction. Therefore the solution for the particle 
trajectory along the x-axis will be independent of the solution for z. The substitution 
of Equations 5.15 and 5.17 into Equation 5.22 for x leads to: 
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The velocity along the z-axis is given by Eq. 5.21. However as the cell changes its 
position along the x-axis the velocity changes we therefore have to take the position 
along x over time into account which leads to: 
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] .             E.q. 5.24 
Equations 5.23 and 5.24 lead to: 
     ( )         .             E.q. 5.25 
The velocity of cells due to the magnetic force is given as   : 
       
      
   
  
       
 ,             E.q. 5.26 
and the position along z as a function of time as: 
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 In order to calculate the targeting efficiency, the initial distribution of cells in 
the tube at the start of the separation length (z=0) needs to be taken into account. It 
is assumed that the cells are randomly distributed over the circular tube cross-
section. If this distribution is projected into the plane we derive:  
     ( )        (   
   
  
) ,            E.q. 5.28 
where  is a weighting factor for the cell number distribution at the start of the 
separation area. The trajectories for cells can be calculated using Eqs. 5.25 and 5.27 
(see Figure 9). If they are weighted with Eq. 5.28 the distribution at the start and end 
of the separation distance can also be calculated. 
A              B 
 
 
 
 
 
 
Figure 9: (A) shows the trajectories for case with 95% targeting efficiency while (B) 
shows trajectories for a case with 5% targeting efficiency. 
 It is assumed that cells which are above or below the z-axis at the end of the 
separation length    (see Figure 8) will end up in their corresponding exit tubes. The 
targeting efficiency can hence be defined at that point as follows: 
         (
            
      
    ) ,            E.q. 5.29 
where             is the number of cells at the end of the tube to which the cells 
were targeted to and        is the total amount of cells in both tubes. The 
subtraction of 0.5 is accounting for the distribution without any steering gradients 
present, which is 0.5 for both exit tubes.  
In order to estimate how much iron oxide needs to be internalised per cell to achieve 
a certain steering efficiency Eq. 5.28 needs to be integrated. For a selected targeting 
efficiency   , the fraction of   
            
      
 cells have to end up in the targeted 
tube. We therefore integrate Eq. 5.28 from -   to     if the magnetic force points 
along the positive x-axis. In this case     indicates the position along the x-axis for 
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which the integral between it and    accounts for    of all cells. We can solve the 
following equation for    : 
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          E.q. 5.30 
If we chose    to be 0.9, than form Eq. 5.28 it follows that   has to be 0.95. 
In order to achieve the 0.9 targeting efficiency, a cell starting at     and z=0 has to 
reach     at the end of the separation length   . Equation 5.27 and 5.25 can be 
solved for  : 
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 .             E.q. 5.31 
From Equations 5.30 and 5.25,   can be calculated as well as the field gradient 
strength or duty cycle necessary to reach a given steering efficiency. For parameters 
used in the model see Table 1. 
Table 1: Model parameters 
Variable Symbol Value Units 
magnetic induction    9.4 T 
gradient strength     0.5 (0.5-10) T m
-1 
saturation magnetisation    314 000 A m
-1 
number of particles per cell   250  
tube radius    0.0004 m 
cell radius    0.000005 m 
average fluid velocity  ̅  0.005-0.08 m s
-1 
separation length    0.06 m 
Duty cycle for steering gradients    2/7  
fluid viscosity   0.0016-0.0024 kg m-1 s-1 
diameter length ratio    5  
cells in one aggregate  1-80  
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5.2.2 Magnetic resonance targeting of cells 
Magnetic steering experiments were performed in the same ways in section 
4.2.4 with minor differences outlined below. In order to investigate the effect of 
different viscosity on targeting efficiency by suspending cells in PBS containing 3% 
foetal bovine serum FBS or 50% FBS. Additionally the effect of increased cell 
concentrations was investigated by doubling the cell concentration. 
5.2.3 Confocal endoscopy 
Confocal endoscopic imaging was performed by Baptiste Allain (Centre for 
Medical Image Computation (CMIC), UCL). The Cellvizio (Mauna Kea Technologies, 
Paris, France), a fibered confocal microscope, was used for the acquisition of dynamic 
microscopic in vitro images of the fluorescent cells. An MR compatible (7 metre long) 
600 micron diameter microprobe, comprising approximately 10,000 coherent optical 
fibres was scanned fibre by fibre via the MKT laser scanning unit behaving as the 
confocal pinhole and objective lens of a conventional near real-time confocal 
microscope for remote acquisitions at 12 frames per second.  
The MR-compatible ProFlex S-microprobe was used which provided an image 
resolution of approximately 4 μm and a circular field of view with a diameter of 500 
μm. The end of the optical fibre was placed into the middle of the inflow channel of 
the flow phantom where a hole was drilled to connect it to the fluid (see Figure 8 and 
Figure 11). The laser scanning unit emitted a laser beam at an excitation wavelength 
of 488 nm and collected the fluorescence signal in a bandwidth of 500 nm to 650 nm. 
Finally, ImageCell Software allowed for real-time visualisation of the microscopic 
images and for manual settings of the contrast. 
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5.3 Results 
Figure 10A shows a comparison between experimental results and 
theoretical predictions for two different cell concentrations, together with the 
theoretical prediction without cell aggregation. This figure demonstrates that the 
theoretical prediction for single cells differs significantly from experimental results, 
indicating that aggregation could play an important role, which may explain the 
discrepancy with the experimental data. When cell aggregation was assumed, cells 
were modelled as prolate spheroids with a polar to equatorial diameter ratio of     . 
Cell aggregation and aggregate shape were included in our model via Equations 15 and 
18. The number of cells N in such an aggregate was derived via fitting the experimental 
data to the model while the diameter length ratio was estimated from confocal 
endoscopy data. For N with the range 60 to 80 coefficients of determination (R2) were 
found to be between 0.93 and 0.97, showing a good agreement between the model 
and experimental data.  
 It should be stated that the numerical validity of the results is dependent on 
the validity of the model assumptions of no gravitational and inertial effects. Neither 
gravity nor inertia are likely to have a significant effect on our predictions, as 
sedimentation is slow and the cells pass through the flow phantom within a few 
seconds. Inertia is neglectable for small cells, especially when the magnetic force is 
applied for the entire time a cell spends in the flow phantom. The assumption of a 
random distribution for cells entering the separation area is harder to assess as a long 
tube is used to connect the phantom with the syringe pump. However, applying 
gradients along the positive or negative x-axis led to similar results indicating no initial 
bias. Finally the assumption of a laminar parabolic flow profile is justified for the fluid 
viscosities and flow rates used in our experiments 
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Figure 10: (A) Comparison of experimental results versus theoretical prediction for 
targeting efficiency. The green dots show the experimental results for a cell 
concentration of 4x106 cells/ml while the blue dots correspond to 2x106 cells/ml, 
vertical bars indicate the standard deviation. Theoretical predictions are shown as 
continuous lines; purple: no cell aggregation, blue: 60 cells aggregated with a prolate 
equatorial to polar diameter ratio of 5, green: 80 cells aggregated with the same 
diameter ratio. (B) The effect of different fluid viscosities on targeting efficiency. Blue 
and red dots show experimental results for PBS+3% serum and PBS+50% serum 
(roughly the viscosity of blood). The continuous lines show the theoretical 
predictions for a viscosity of 0.0016 Pa s and 0.0024 Pa s assuming no changes in 
aggregate size. Blue and red dots show the measured targeting efficiency (mean ± 
SD, n=6) 
A minor increase in targeting efficiency was observed when the cell 
concentration was doubled. This indicates that aggregate sizes might not change much 
for the increased cell concentration. The theoretical model used a constant aggregate 
size which is likely to be incorrect particularly for higher flow rates where increased 
shear forces overcome magnetic dipole interactions and hence aggregation (see 
confocal results below). We therefore see a discrepancy between the model and 
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experimental data starting between 5 and 6 cm/s for 2x106 cells/ml and 6 and 8 cm/s 
for 4x106 cells/ml. Figure 10B shows experimental results and theoretical predictions 
for two different fluid viscosities. The increases in fluid viscosity led to a modest 
decrease in targeting efficiency. Changing the fluid viscosity does affect the drag force 
which needs to be overcome and to a lesser degree cell aggregation. Increasing the 
fluid viscosity to the viscosity of blood did only lead to a slight reduction in targeting 
efficiency (Figure 10B). 
This can be seen in Figure 10B for which the aggregate size was kept at 60 cells 
with a diameter to length ratio of 5 and measured fluid viscosities were used to 
calculate theoretical targeting efficiencies. These predictions fit the experimental data 
assuming that the aggregate size does not change significantly. 
A confocal endoscope was used to investigate cell aggregation. This system 
operates as a conventional confocal microscope as the coherent fibre bundle is rapidly 
scanned point by point, conducting light to and from the sample, acting as both the 
objective lens and the confocal pinhole. Figure 11 shows single frames from videos 
taken at different fluid velocities without a magnetic field present and with a 
homogenous magnetic field of 9.4T (bore of the MRI scanner). For fluid velocities of 1 
cm/s and 2 cm/s (Figure 11A and B) cells travelled as aggregates in the magnetic field 
of the MRI scanner; these aggregates showed roughly elongated shapes containing 
between 20-80 cells. We estimated the diameter to length ratio of these aggregates to 
be around 5. For the same experiments conducted without a magnetic field (outside of 
the MRI scanner), no cell aggregation was observed.  
When the fluid velocity was increased to 4 cm/s (Figure 11C) cells did not form 
large aggregates but rather chain-like aggregates with 2 to 10 cells arranged into a 
chain. The transition between large aggregates (several 10s of cells) and smaller chain 
like aggregates was observed at a fluid velocity of approximately 3 cm/s. It has to be 
accepted that the imaging fibre was introduced into the flow phantom (see Figure 
11D) and may have caused some minor flow disturbances. 
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Figure 11: Singe frame images from confocal endoscopy videos acquired at a frame 
rate of 12 images per second for different fluid velocities without a magnetic field 
and in an homogeneous magnetic field of 9.4T (inside the bore of an MRI scanner). 
The left column corresponds to no magnetic field while the right column corresponds 
to 9.4T. A: flow rate of 1 cm/s, B: 2 cm/s, C: 4 cm/s. The scale bar in the lower right 
hand corner of each image indicates 50 µm while the field of view is 500 µm with a 
depth perception of about 100 µm. The arrow in the right column figure A indicates 
the orientation of the magnetic field for the whole right column. D shows a 
schematic drawing how the microprobe was introduced into the flow phantom and 
how chain like aggregates are aligned with the main field of the MRI scanner (B0). In 
the lower right hand corner chain like aggregates of cells are magnified by a factor of 
three (3X). 
 
The mathematical model permits the investigation of the effects of different 
parameters on targeting efficiency (see section 5.2.1). Figure 12A for example shows 
the volume fraction that iron oxide particles would need to take up in a cell to reach a 
targeting efficiency of 90% for different gradient amplitudes. For this plot no cell 
aggregation was assumed. 
Figure 12B shows the effect of the aggregate geometry on the targeting 
efficiency. As the magnetic force is a volumetric force and the drag force is dependent 
on the projection surface in flow direction, the deviation from a spherical object to an 
elongated one reduces the targeting efficiency. From the analysis of our videos we 
observed that the equatorial to polar diameter ratio is approximately five. If 40 cells in 
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one spherical aggregate are necessary to explain the experimental results shown by 
the blue line in Figure 10A, the number of cells in one aggregate with a diameter to 
length ratio of 5 will increase to 60. The diameter to length ratio of aggregates is 
dependent on the polydispersity of the solution. It might therefore be possible to add 
a small concentration of ferrofluid to increase the size of these aggregates and reduce 
their diameter to length ratio.  
 
Figure 12: (A) The effect of different polar to equatorial diameter ratio on targeting 
efficiency assuming the total number of cells in an aggregate is constant. (B) 
Predictions for the volume fraction on iron oxide in cells necessary to reach a given 
targeting efficiency without cell aggregation for different gradients strengths at a 
duty cycle of 50%. gx: gradient strength T/m.  
5.4 Discussion 
The comparison between experimental results and theoretical predictions 
showed that aggregation is a likely candidate to explain the discrepancies between the 
two. Predictions fit the experimental data assuming that the aggregate size does not 
change significantly when viscosity and cell concentration are changed. The 
importance of magnetic dipole interactions for targeting applications have been 
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described previously 144;232;236. Also there have been previous publications where a 
similar bifurcation has been modelled but in the context of permanent magnets and 
without cell aggregation 237;238. However, in comparison to these studies we used cells 
with internalised particles and not magnetic particles alone. This changes aggregation 
behaviour as particles are kept at greater distances due to other cellular 
compartments and their membranes, while aggregated cells might stick together more 
readily depending on the cell line used. Forces which oppose aggregation of particles 
are electrostatic and van der Waals forces. These forces have a shorter range 
compared to magnetic dipole interactions and are shielded to a large extend by the 
cells. We should therefore expect slight differences between the aggregation 
behaviour of ferrofluids and cells even if the same iron concentration per unit 
suspension volume is used.  
Mathieu et al. 232 showed that the average chain length of iron oxide particles 
without fluid flow at a concentration of 0.6 mg/ml and 0.4 T was about 31µm and for 
1.13 mg/ml at a flow rate of < 1.2 cm/s in an 1.5 T MRI scanner approximately 650 µm. 
In our study, we reached an iron concentration, per unit suspension volume, of 
approximately 0.5 mg/ml in labelled cells and observe aggregates with a length of 150-
250 µm. This difference could be attributed to the internalisation of particles by cells 
and the difference in fluid velocity, which may increase aggregation. We also observed 
that, cells with internalised particles showed different aggregation behaviour at lower 
flow rates while aggregation at higher flow rates follows a similar (chain) pattern as 
observed for ferrofluids. The aggregation behaviour observed for low flow rates might, 
in part, be caused by the strong field gradients at the bore of the magnet. These 
gradients will induce transverse motion which will increase the likelihood for 
aggregation as cells will come close enough to other cells to experience their magnetic 
dipole moment.  
Cell aggregation is clearly an important factor for cell targeting using MRT and 
will always be present unless very dilute suspension is used or cells contain only a very 
low amount of iron oxide are used. The higher magnetophoretic velocity of aggregates 
allows for increased targeting efficiency at higher flow rates. This can be further 
enhanced by increasing the cell concentration in the injection solution. However, if 
small vessels are to be targeted, large aggregates might perturb blood flow leading to 
vessel occlusion. Although shear forces will increase in small capillaries, it is not certain 
if these forces will be big enough to disaggregate cells. However, the nanoparticles 
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used for these experiments are superparamagnetic and the removal of the subject 
from the strong field of the MRI scanner would lead to the decay of dipole interactions 
and thus the cells should be able to disperse. This should also be the case for 
ferrofluids. However, there is an additional risk that during the contact time between 
cells, some may have bound together too strongly to be dispersed by the fluid flow. 
This is of particular relevance for MRT, but it will also be of importance for magnetic 
targeting applications that use permanent or electro magnets. Further research will be 
needed to address this question.  
The theoretical model shows that achieving high targeting efficiency at higher 
fluid velocities will be difficult. However, it will be necessary to achieve higher 
targeting efficiencies for such velocities if this is to be applied for bigger blood vessels. 
One option would be to increase the gradient strength of the system as indicated in 
Figure 12B. This can be achieved easily for small bore MRI systems but will be difficult 
for human MRI systems. Exploring possibilities to aggregate cells to bigger clumps for 
steering in big vessels might be a more favourable option to increase targeting 
efficiency. Another possibility might be to reduce the blood flow rate temporarily via 
the catheter used for cell delivery if that is acceptable from a medical perspective. 
Achieving high targeting efficiencies in major blood vessels is not only limited due to 
increase blood flow rates which reduce the available time to deflect a cell towards on 
exit branch of a bifurcation but also by turbulences in the fluid flow which might defect 
a cells to the opposite exit branch. 
 
5.5 Conclusions 
The model above describes the steering efficiency of magnetically labelled 
cells inside a small bifurcation in the context of MRT. Such a model could be used for 
the implementation of an active control strategy for cell delivery using MRT. This 
model takes cell aggregation into account and models these aggregates as prolate 
spheroids. Predicted targeting efficiencies agree with experimental results when cell 
aggregation is taken into account, highlighting the importance of cell aggregation in 
this context. This aggregation behaviour did not change much when cell concentration 
or fluid viscosity where changed in our model or experimental setup.  
Aggregation of cells inside the MRI scanner was confirmed via confocal 
endoscopy. Confocal endoscopy showed aggregate sizes at lower flow rates which are 
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in the predicted range of our theoretical model. A transition from large aggregates 
containing up to 100 cells to small chain like aggregates with up to 10 cells at flow 
rates of > 4-6 cm/s was found.  
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6 Magnetic cell delivery to lower leg arteries 
Chapters four and five were focused on the use of an electromagnet system 
(MRI scanner) for magnetic cell delivery. In contrast to these chapters, the current 
chapter will focus on the feasibility of magnetic cell delivery to human lower leg artery 
using permanent magnets. A range of potential magnet arrangements has been 
evaluated for a realistic vessel configuration using a finite element approach. The best 
performing magnet arrangement has been used for fluid dynamics simulation to 
investigate if labelled cells can be captured for flowing blood. Finally the behaviour of 
labelled vessel close to the arterial wall has been simulated using a fluid structure 
interaction model. 
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6.1 Introduction 
The problem of restenosis and the potential of cellular therapies such as EPC 
delivery has been outlined in chapter one. Based on that premise this study will 
investigate the feasibility of magnetic cell delivery in that context theoretically. Despite 
the potential advantages of magnetic cell delivery, no clinical trials have been 
conducted so far. One of the key reasons for this lies in the nonlinearities of the 
scalability of magnetic delivery strategies. A common limitation of all strategies is the 
rapid decline in magnetic field and gradient strength with increasing distance from 
their source. Accordingly strong magnetic forces can easily be achieved in small animal 
models but are almost impossible to achieve for human dimensions.  
This study starts with the hypothesis that optimisation and feasibility 
assessment of magnetic cell delivery should start with human dimensions followed by 
a scale-down to an appropriate animal model239-241, such that the forces acting on cells 
are kept constant if possible. Following this hypothesis, the aim of this study is to 
investigate the theoretical feasibility of magnetic cell delivery to the arteries of the 
lower leg as a potential supplementary treatment after balloon angioplasty for PAD, in 
order to improve re-endothelialisation and increase vessel patency. 
In this study MRI angiograms were acquired from healthy volunteers whose leg 
dimensions were selected to best reflect diabetic patients with PAD. The resulting 
angiograms were used to define the position of the three major vessels in the lower 
leg (peroneal, anterior and posterior tibial artery) and the skin in 3D. Three 
dimensional vessel positions were used for a finite element model (FEM) optimisation 
of a range of different magnet configurations in 3D. A computational model of the 
blood vessels, together with boundary conditions from magnetic resonance phase-
contrast images were used for computational fluid dynamics (CFD) simulations. This 
allowed the comparison of the fluid and magnetic forces acting on labelled cells, 
allowing an estimation of the maximum distance for cells drifting near the vessel wall 
to be captured by the magnetic field. Moreover the best performing design was scaled 
down for a rabbit arterial injury model of the common carotid artery whilst 
maintaining a constant force acting on cells. 
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The hypotheses for these experiments were: 
 Finite element models can be used to optimise potential magnet 
arrangements for a specific application. 
 Computational fluid dynamics can be used for theoretically assessments 
of the feasibility to capturing cells from the blood stream under realistic 
flow conditions. 
 A magnet arrangement optimised for human dimensions can be scaled 
down to the dimension of an animal model while keeping forces acting on 
cells essentially constant. 
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6.2 Materials and Methods 
6.2.1 Dimensions of legs with PAD  
In order to obtain an estimate for the dimensions of diabetic PAD legs the 
circumference of legs below the knee, at the maximum Gastrocemius (calf muscle) 
circumference and above the ankle, were measured following the protocol approved 
by the department of health and UCL ethics committee from twenty consecutive 
outpatients (59 ± 12 years, six female) who gave their consent. All of these patients 
had ulcers or gangrene and a history of diabetes mellitus. Informed written consent 
was obtained from three healthy volunteers (25 ± 4 years, two female) for MRI data 
acquisition to provide an anatomical model of the arteries in the lower leg. These 
MRI scans were acquired using a protocol approved by the department of health and 
UCL ethics committee.  
6.2.2 Acquisition of human MR data 
Human MRI data was acquired by Anthony Price (Robert Steiner MRI Unit, 
Imaging Sciences Department, Hammersmith Hospital Campus, Imperial College 
London) Magnetic resonance imaging was performed on a 3 T Philips scanner (Best, 
The Netherlands) using an 8-channel phased-array receive coil. Axial 2D time-of flight 
angiography images were acquired downstream of the branching of the peroneal and 
posterior tibial arteries. One hundred consecutive slices were acquired using the 
following parameters: field of view (FOV) 120x120 mm, slice thickness 2 mm, matrix 
size 160x160, flip angle (FA) 50°, echo time (TE) 4 ms, repetition time (TR) 21 ms, 
reconstructed to 0.25x0.25x2 mm. 2D phase contrast (velocity encoded) gradient 
echo images were acquired for the inflow and outflow slice of this volume. Twenty 
time frames were acquired to cover one cardiac cycle using echocardiography 
retrospective gating and the following imaging parameters: TR 12 ms, TE 7 ms, 
number of signal averages (NSA) 3, FA 10°, velocity encoding 80 cm/s, reconstructed 
to 0.5x0.5x2 mm. 
6.2.3 Acquisition of rabbit MR data 
A sacrificed rabbit (2 kg) was scanned using a 9.4T Agilant Technologies 
VNMRS scanner (Palo Alto, CA) in order to generate a data sate for scale down of the 
simulations to a suitable animal model. Consecutive axial gradient echo slices were 
acquired to cover the whole neck area with a 72 mm volume coil (Rapid Biomedical, 
Rimpar, Germany) using the following imaging parameters FOV 60x60 mm, slice 
thickness 1 mm, Matrix size 512x512, TR 1370 ms, TE 7 ms, NSA 8, FA 30°. 
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6.2.4 Magnet optimisation using finite element methods 
Permanent magnets offer high field strength without the need for electric 
power or cooling. However, as there are many potential arrangements, a rational 
optimisation is necessary.  
We used commercially available finite element modelling software Opera 
v12, TOSCA (Kidlington, UK) to calculate the magnetic field distribution in three 
dimensions for four basic geometries: Halbach cylinder (in this study always a hollow 
cylinder), linear Halbach array, equilateral triangular rod and magnetic rod (see 
Figure 13). In order to test for mesh independence of our finite element simulations, 
all element sizes were halved for one simulation for each geometry which led to an 
error in the magnetic force of < 0.7% on average.  
 
Figure 13: Geometrical arrangement of different magnet shapes around a human 
leg. A magnetic resonance image is shown in the centre of the Halbach cylinder to 
indicate the three major blood vessels of the lower leg. Open arrows indicated the 
magnetisation orientation of different elements. Note that only one of the basic 
geometries was used at one time for finite element simulations. 
The Halbach cylinder is a one sided flux concentrator with continuously 
changing magnetisation direction112 ( ) following, 
         ,                 E.q. 6.1 
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with   as a positive integer between 2 and 4 for internal flux concentration and   the 
angel for the position around a circle. However, as this would be difficult to build, in 
practice Halbach cylinders are built out of segments with a constant magnetisation 
using equation 6.1 for the centre of each element. This leads to a reduction of the 
flux density112 following 
B(n)   
   (    )
    
 ,                E.q. 6.2 
where    stands for the magnetisation of a Halbach cylinder with continuously 
changing magnetisation orientation and   for the number of elements.  
A linear Halbach array is also a one-sided flux concentrator which follows the 
same principle as the Halbach cylinder (magnets with sinusoidal magnetisation 
produce single sided fields). The magnetisation orientation makes one full rotation 
along L (one wavelength) focusing all magnetisation on the lower side of the array.  
For each of the four geometries tested, the magnets were arranged around 
an air cylinder (placeholder for a human leg) with a radius of r1=80 mm and a length 
of L=200 mm (for a full list of model parameters see Table 2) while r2, r3, c and a (see 
Figure 13) were increased to calculate the magnetic field for an increasing magnet 
volume. An MRI angiogram of a leg was centred in the air volume to get blood vessel 
positions in 3D space. For each of the three vessels considered, magnetic forces 
acting on cells in the centre of them were calculated at 20 points along their 
centreline. Magnets arranged around the air cylinder were rotated 360° around its 
long axis in 36 steps. Forces acting on cells for 60 points (20 points, 3 blood vessels) 
of each rotation step were evaluated. The rotation which generated the highest force 
over all 60 points was selected and their average has been used for average force 
plots. Force calculations were performed using Matlab (R2010a, Natick, MA). 
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Table 2: Physical parameters used for this study 
Parameter Symbol Value Units 
Length for magnets and vessel section L 200, 40 (30)
*
 mm 
Halbach cylinder inner radius r1 80 (54-98), 25
*
 mm 
Halbach cylinder outer radius r2 140 (82-240), 29
*
 mm 
Magnetic rod radius r3 115 (18-226)
*
 mm 
Linear Halbach array height a 259 (6-1005)
*
 mm 
Linear Halbach array width b 160 (40-160)
*
 mm 
Equilateral triangle side length c 309 (75-609)
*
 mm 
Outer radius endplate r4 130 (100-140)
*
 mm 
Endplate angle α 45 (30-90)
*
 ° 
Endplate hight h 25 (5-50)
*
 mm 
Residual flux density NdFeB† Br 1.36 T 
Coercivity NdFeB
†
 Hc 1051 kA m
-1
 
Relative permeability NdFeB
†
 μr 1.04 - 
Residual flux density sintered ferrite Br 0.37
*
 T 
Coercivity sintered ferrite Hc 240
*
 kA m
-1
 
Relative permeability sintered ferrite μr 1.21
*
 - 
SPION
‡
 crystal size D 8.8 nm 
Saturation magnetisation iron oxide Ms 354 kA m
-1
 
Temperature T 300 K 
Magnetic permeability free space μ0 4*π*10
-7
 H m
-1
 
Boltzmann constant kb 1.38*10
-23
 J K
-1
 
Cell radius Rc 10 μm 
Cell density c 1100 kg m
-3
 
Young’s modulus cells - 10 kPa 
Poisson ratio cells - 0.45 - 
Dynamic viscosity, fluid   0.0039 kg m s-1 
Fluid density f 1080 kg m
-3
 
*
 Bold numbers indicate dimensions which were used for the comparison of magnet 
arrangements with the same volume. Blue numbers indicate values used for the 
rabbit scale model. † NdFeB Neodymium Iron Boron, ‡ SPION superparamagnetic iron 
oxide nanoparticles 
 All of these geometries, except for the Halbach cylinders have a one sided 
distribution of magnet material. In order to investigate different arrangements of the 
basic geometries a magnet volume was selected (6600 cm3) and kept constant while 
the number of basic geometric elements (linear arrays, rods, triangular rods) around 
the air cylinder was increased. For example 1, 2, 4, 6, 8, 10, 12 magnetic rods were 
equally spaced around the air cylinder while r3 was decreased to keep the total 
magnet volume constant. The magnetisation was orientated towards the centre for 
n=1, following a dipole orientation for n>1 and following a quadrupole orientation for 
n>4 as given by, 
      (  (   ))  ,                E.q. 6.3 
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with     for a dipole and     for a quadrupole.  
For the Halbach cylinders, a k3 variety was used with decreasing   leading to a 
magnetic hollow cylinder with a single magnetisation orientation for    . 
Magnetisation orientations for the linear Halbach array were kept constant, but 
  and   were adjusted in order to fit   linear arrays around the air cylinder.  
 To address the scalability of a Halbach cylinder k3 for a range of potential 
human leg diameters the ratio of r1/r2 was kept at 0.62 while r1 was increased from 
54 to 98 mm. 
 All of these simulations were done in 3D using the demagnetisation curve of 
commercially available Neodymium-Iron-Boron magnet standard grade 45SH 
(remanence magnetisation Br=1.36 T, coercivity Hc=1051 kA/m, relative permeability 
μr=1.04)
1  
 Finally simulations for the scale down of a Halbach cylinder k3 for a rabbit 
common carotid artery model, with r1=25 mm and L=40 mm, were performed using 
the demagnetisation curve of commercially available magnetic sintered ferrite 
(Br=0.37 T, Hc=240 kA/m, μr=1.21)
2. 
6.2.5 Model construction for computational fluid dynamics 
In this study, the geometry of the arterial system has been simplified from a 
three-dimensional tube to a two dimensional channel in order to reduce the 
computational cost of the simulations. The geometry has been taken as a channel 
section 2.2 mm in diameter (according to the MR angiogram); 200 mm in length and 
0.11 mm in width (see Figure 21). The fluid has been modelled as incompressible 
Newtonian fluid with a density of 1080 kg m-3 and a viscosity of 0.0039 kg m s-1 
(density and viscosity of blood). The volume was meshed using mixed tetrahedral and 
hexahedral elements (Figure 21) and was tested for mesh independence by applying 
a constant velocity boundary condition at the inlet of 0.25 m s-1 (maximum difference 
between inflow and outflow boundary value), 0 Pa pressure at the outlet and 
symmetry boundary conditions enforcing the two-dimensional flow. Velocity 
variations down the centre of the channel were assessed and the mesh was 
determined sufficiently fine when the maximum percentage difference between 
                                                          
1 Neodymium-Iron-Boron Magnets. http://www.tdk.co.jp/tefe02/e331.pdf 
2 Sintered ferrite magnets. http://www.magnetsales.co.uk/sintered-ferrite.htm 
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successively finer meshes was found to be less than 1%. The final mesh consisted of 
156155 nodes and 419191 elements. 
 Flow profiles were extracted from phase contrast images using the freely 
available software Segment version 1.8 R0462 (http://segment.heiberg.se)242. The 
average velocity recorded at both inlet and outlet was fitted to an 8th order Fourier 
series using MATLAB. These were then applied to the fluid domain as inlet and outlet 
velocity boundary for the channel. 
 For the rabbit common carotid artery, a channel diameter of 1.5 mm, a length 
of 30 mm and a width of 0.11mm were used. For the inflow boundary an 
interpolated spline fit was performed using MATLAB with the flow profile from Cui et 
al.243 while the outflow pressure boundary was set to 0 Pa. 
6.2.6 CFD simulations and post processing 
Computational fluid dynamics modelling was performed by Kevin Lau (UCL 
mechanical engineering) using ANSYS CFX 11.0, a finite volume based computation 
fluid dynamic solver, which solves the unsteady equations for mass and momentum 
conservation of an incompressible fluid. The unsteady flow dynamics are solved by 
advancing the solution with time steps of 0.01 s. At each time step the residuals of 
the non-linear system are reduced till either the maximum of the residuals of both 
the velocities and pressures were less than 10-6 or 100 convergent iterations had 
been performed. In order to assess the periodicity of the solution, the boundary 
conditions were repeated for three cardiac cycles. 
Post-processing of this data was performed using EnSight 9.1.2, which was 
used to model particle traces under the application of magnetic forces. Cells were 
simulated as massed particles (  ), which experience drag (  ) and magnetic forces 
(  ); 
             (     )   ,                E.q. 6.4 
       
         ( )
  
(
 
| |
  )    ,               E.q. 6.5 
      
  
  
         .                E.q. 6.6 
Constant magnetic forces between 12 and 120 pN were applied corresponding to an 
iron load of 15 - 150 pg/cell. The path of each magnetically labelled cell was traced at 
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each time step, displaying how the particle path would evolve under both fluid and 
magnetic forces. 
6.2.7 Behaviour of a cell close to the arterial wall 
A fluid structure interaction model was used to model the behaviour of a cell 
near a vessel wall. As this requires both the structural deformation and fluid-
structure interaction, the explicit finite element code LS-DYNA was used. Fluid 
structure interaction modelling was performed by Kevin Lau (UCL mechanical 
engineering). A cell was modelled as an isotropic elastic body with a density of 1100 
kg m-3, Young’s modulus of 10 kPa and a Poisson ratio of 0.45. A commonly reported 
Young’s modulus for human umbilical vein endothelia cells244 was chosen as no data 
for EPCs could be found. 
A uniform inlet velocity of 0.01 m s-1 was applied which corresponds to the 
maximum value of the velocity at the top of the fluid domain assuming that the full 
velocity profile in the channel is parabolic. The simulations were run until a linear 
velocity gradient was formed across the inlet. Magnetic forces were applied to the 
cell by applying a uniform and constant force to each node in the cell, pulling it 
towards the wall. 
Fluid-structure interaction was performed using a penalty coupling method, 
whereby the force applied to both fluid and structural domains was determined by 
calculating the level of fluid penetration into the solid domain. The fluid model of LS-
DYNA is a compressible model and was defined with the following parameters: 
density 1080 kg m-3, dynamic viscosity 0.0039 Pa s and a bulk modulus of 22 GPa. The 
value of the bulk modulus directly controls the maximum timestep in explicit time 
integration, thus in order to obtain simulations that runs in reasonable time frames 
this value was reduced to 1% of its true value, which was found to have no effect by 
comparing the numerical solution to the analytical solution of channel flow. 
6.3 Results 
6.3.1 Magnet optimisation 
The maximum calf muscle radius measured for our patient group was 98 mm 
(see Table 2). We therefore choose a radius of 80 mm for our initial comparison of 
different magnet arrangements, as these would accommodate 90% of our 
population. As our patient group is limited it may not reflect the real variability of 
PAD patients, we therefore investigated the scalability of a magnet (see Figure 19).  
89 
 
Table 3: Leg dimensions for a small group of patients with peripheral arterial 
disease 
n=40 radius below 
knee 
maximum 
radius 
radius above 
ankle 
radius ankle 
mean ± SD [mm] 59 ± 10 60 ± 11 38 ± 7 43 ± 5 
min [mm] 37 46 25 35 
max [mm] 91 99 59 59 
 
Figure 14 shows the average magnetic force acting on cells in the anterior 
tibial artery, posterior tibial artery and peroneal artery, for six magnet arrangements, 
with increasing magnet volume. For magnet volumes below 1000 cm3, the magnetic 
rod, the Halbach cylinder k3 and the linear Halbach array generate a similar force. 
However for larger magnet volumes the Halbach cylinder k3 generates a stronger 
magnetic force than any other arrangement, followed by the Halbach cylinder k2. No 
change in magnetic force was notable above 10000 cm3 from the magnetic triangle, 
magnetic rod, linear Halbach array or Halbach cylinder k4.  
 
Figure 14: Average forces acting on magnetically labelled cells in the three major 
arteries of the human leg for different magnet arrangements with increasing 
magnet volume. All Halbach cylinders consisted of 12 elements while one magnetic 
rod and triangular magnetic rod were used. The linear Halbach array consisted of 5 
elements. 
Figure 15 shows the effect of multiple elements of basic magnet 
arrangements on the average magnetic force acting on a cell. The Halbach cylinder k3 
again outperforms all other arrangements, provided it is constructed of more than six 
elements (see equation 6.1). For less than six elements, the magnetic rods are 
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superior, closely followed by linear Halbach arrays. A quadrupole arrangement (see 
equation 6.3) of magnetic rods comes closest to the Halbach cylinder k3 for more 
than six elements.  
 
Figure 15: Average magnetic force produced by an increasing number of the basic 
geometrical magnet arrangements arranged symmetrically around the leg. The 
magnet volume is constant (6600 cm3) for all of these arrangements. Note that for 
the Halbach cylinder the cylinder was not modified, only the number of elements it 
was divided into was changed. As outlined section 6.2.4 the magnetisation 
orientation of the Halbach cylinder follows k3 for more than 6 elements. 
 Figure 16 shows the force profile for a linear Halbach array and for the Halbach 
cylinders k3 and k4 across the centre of the air cylinder. Radial distances for blood 
vessels from the centre axis of the leg are shown as well to visualise the expected 
force for such radii. The mean distance between anterior tibial artery, posterior tibial 
artery, peroneal artery and the skin for three angiograms was 32 ± 7 mm. Note that 
the force produced by cylindrical magnet arrangements is rotationally symmetric 
while the force from the linear array continues to fall with increasing distance. The 
Halbach cylinder k3 produces a fairly constant force over a wide range of its internal 
radii due to its linear field gradient profile.  
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Figure 16: Example force profiles for different magnets using the same volume of 
magnetic material (6600 cm3) All Halbach cylinders consist of 12 elements while the 
linear Halbach array consists of five elements. The radial position of the major 
lower leg blood vessels have been plotted to indicate their position within the 
magnet. 
 An infinite Halbach cylinder would have a perfectly symmetric field 
distribution. However, the finite length of real cylinders leads to flux loss at the ends 
and hence to decreased field and gradient strength. Figure 17 shows a comparison of 
different cylinder lengths for Halbach cylinders k3. Additionally the effect of 
endplates as outlined by Bjørk et al.245 has been assessed. Vertical black lines have 
been drawn in Figure 18 to indicate the length of the blood vessel segments used for 
CFD simulations. All force profiles shown in this figure are for a line with a radius of 
15 mm away from the centre. Increasing the cylinder length beyond the length of the 
vessel segment leads to considerable improvements in the homogeneity of the force. 
The use of endplates as indicated in Figure 18 has the benefit of minimising the use 
of magnetic material while increasing the force acting along the line. However, the 
linearity was not improved to the same degree as for the extended Halbach cylinders. 
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Figure 17: Linearity of the magnetic force along the z-axis of k3 Halbach cylinders 
with different lengths and endplates. The definition of the endplate height and the 
circumferential angle α are shown in Figure 18. 
 
 
Figure 18: Geometrical arrangement of endplates on a Halbach cylinder k3. 
Endplates are made of the same magnetic material as the Halbach cylinder. Open 
arrows have been used to indicated the magnetisation orientation of the four 
endplates. 
6.3.2 Scalability of magnetic forces 
Two aspects of scalability are addressed in this study; changing the inner 
diameter of a Halbach cylinder k3 to accommodate different human leg diameters 
and secondly the scale down for an animal model.  
Figure 19 shows the slow decline of the magnetic force as the inner radius is 
increased from 54 to 98 mm for Halbach cylinders k3 with a r1/r2 ratio of 0.62. 
Magnetic forces acting on cells for increasing leg diameters decrease from 14 pN to 6 
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pN. At the same time the necessary magnet volume increases from 4000 to 10000 
cm3.  
 
Figure 19: Average magnetic forces produced by Halbach cylinders k3 with different 
inner diameters illustrating the scalability for different human leg diameters. A 
constant ratio between inner and outer diameter of 0.62 was used for all Halbach 
cylinders. The black horizontal line indicates an inner radius of 80 mm 
corresponding to the sixth circle on the Halbach cylinder k3 line of Figure 14.  
 Figure 20 shows the force profiles along the radius for two Halbach cylinders 
k3. The first one has an inner radius of 80 mm and is made of neodymium iron boron 
while the second one has an inner radius of 25 mm and is made of sintered ferrite. 
The outer radius of the smaller cylinder has been adjusted in order to match the 
force acting on cells of the bigger cylinder. As the smaller cylinder is intended for a 
rabbit common carotid injury model, the radial distance of the right carotid from the 
neck centre line has been added. It can be appreciated that the forces acting on cells 
in the carotid artery would be similar to forces expected for the human lower leg 
arteries (see Figure 16). 
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Figure 20: Force profile for a Halbach cylinder k3 and a scaled down version for a 
rabbit injury model. The radial position of the right common carotid artery has 
been plotted to indicate the force cells would experience along the centreline of 
the artery. 
6.3.3 Magnetic attraction of cells to the arterial wall 
Computational fluid dynamics modelling was used to investigate the behaviour 
of magnetically labelled cells in an artery with pulsatile flow and an external 
magnetic field. Figure 21 shows a small section of the mesh in the flow channel 
(approximation for the posterior tibial artery) and seed points which were used to 
release and track the movement of cells. Cells were seeded 20 mm inwards of the 
flow channel to avoid disturbances from the inlet.  
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Figure 21: Close up of the meshed artery channel with the different cell seeding 
point indicated by red dots. The size of this section with respect to the whole artery 
channel is indicated by a black box at the bottom of the figure. 
Figure 22A and C show the trajectories for cells experiencing a magnetic force 
of 48 pN (60 pg iron/cell) during maximum forward flow (A: towards foot) and 
backward flow (C; towards knee) respectively. Cells which are within 1% of the 
chamber radius from the wall will hit the wall, while cells released at 2.5% from the 
wall will not. Figure 22B and D show the trajectories for cells exposed to a magnetic 
force of 120 pN (150 pg iron/cell) along the x axis (up) as for A and C. Cells seeded at 
0.5 and 1% from the wall contact the wall quickly (in one forward cycle) while cells 
seeded at 2.5% require both forward and backward cycles to contact the wall. For 
this case the total capture efficiency over one cardiac cycle would be 6.25% of all 
cells passing through the channel while a magnetic force of 12 pN per cell would lead 
to a capture efficiency of < 0.5%. 
The plots in the centre between A-B and C-D show the flow profile for the 
inflow and outflow which have been used in these simulations; these were obtained 
from a 200 mm section of the posterior tibial artery from a single volunteer. Portions 
of these flow curves have been shaded to indicate the time points within a cardiac 
cycle for which the flow profiles are shown.   
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Capture efficiencies for magnetically labelled cells in the rabbit common 
carotid artery with an applied magnetic force of 12 pN and 120 pN per cell were < 
0.5% and 100% over one cardiac cycle respectively (data not shown).  
 
Figure 22: Trajectories for cells labelled with 60 pg iron per cell at the time of 
maximum forward flow A (towards the foot) and maximum backflow C are shown. 
Figure B and D show the trajectories for cells labelled with 150 pg iron per cell. The 
magnetic force is orientated up for all plots, as indicated by the arrow in the lower 
left corner. Other arrow heads indicate the velocity of the fluid, which are scaled in 
magnitude. The two plots in the middle show the inflow and outflow profile for a 
200 mm anterior tibial artery section over three cardiac cycles, the current time 
point of the simulations indicated by the difference in shading. Plot A-B show the 
flow field 1 second after the first heart beat, whilst C-D show the flow field 1.3 
second after the first heart beat. 
6.3.4 Physical behaviour of a cell close to the arterial wall 
Fluid-structure interaction simulations were performed to investigate the 
behaviour of a magnetically labelled cell close to the arterial wall as the resolution of 
the CFD simulations are insufficient to address this issue. A uniform magnetic force 
was applied on all nodes of the structural model of the cell while a constant 
boundary condition was applied for the fluid flow and allowed to evolve.  
Figure 23 shows the mesh and the geometrical arrangement at the start of 
the simulation with the cell at 5 μm from the vessel wall. The magnetic force pulls 
the cell to the wall (contact occurs in < 0.05 ms) and together with fluid forces this 
leads to the flattening of the cell. Here friction between the cell surface and the wall 
has been neglected, which results in the cell rolling with minimal displacement along 
the channel ( 3 μm over 1 s). A snapshot for the fluid field at the rolling condition is 
shown in Figure 24.  
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Figure 23: Finite element mesh of the cell (structure) and fluid used for fluid-
structure interaction simulations. A constant fluid velocity is applied on the right 
side. Here the magnetic force is orientated downwards. 
 
 
Figure 24: Fully develop fluid velocity field around the cell (0.4 sec after simulation 
start). The cell has been attracted to the wall and flattened by the magnetic force 
acting on the cell. The fluid forces result in the slow rolling of the cell during the 
simulation as the wall of the artery has been modelled as frictionless. 
6.4 Discussion 
Overcoming fluid forces is of major importance for most magnetic cell or drug 
targeting approaches. It is therefore important to optimise all important components 
involved such as cell labelling, magnet actuation device design and delivery protocol. 
Furthermore, any such study needs to follow a thorough parameter optimisation, 
which will be dependent on the geometry of the targeting tissue. While there is a lot of 
literature on particle optimisation81;246-248 and cell loading44;88, there is little material 
documenting magnet optimisation112;245;249. Additionally previous reports have only 
tested a small number of geometric arrangements.  
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The optimisations showed that for arteries in the legs, a Halbach cylinder k3 
outperforms all other potential arrangements of permanent magnets. This would also 
be true for other arrangements where the arteries are not close to the skin. It is 
advantageous that Halbach cylinders produce fields with rotational symmetry as this 
makes positioning of the magnet straightforward. Linear field gradients produced by 
the Halbach cylinder k3 led to constant forces over a wide range where the magnetic 
particles are fully magnetised. However, this comes with the drawback that the force 
will fall to zero close to the centre. If a human leg is centred in a Halbach cylinder, the 
peroneal artery will be closest to the centre and can cross the centre line (data not 
shown). This is not desirable as cells might be washed away but clinical experience 
suggests that the reendothelialization of the posterior and anterior tibial artery is of 
greater importance20. Hence it might be acceptable to have some areas of the 
peroneal artery where magnetic cell delivery would be less efficient.  
As mentioned above, fluid forces are a major obstacle for magnetic cell and 
drug targeting. Consequently, it is important to consider them during the optimisation 
process. CFD offers interesting opportunities to study magnetic targeting in fluids. This 
approach has previously been used for the targeting of magnetic particles in 
experimental arrangements121;236;250, but has not been combined with patient derived 
geometry and blood flow data for the purpose of cell targeting. The CFD model in this 
study was built from MR data which allowed the theoretical assessment of cell 
targeting efficiency for the human lower leg arteries. For a healthy volunteer the fluid 
forces were dominant and led to a targeting efficiency of 6.25% for strongly labelled 
cells. Cells which were close to the vessel wall (< 0.5% of the radius) were attracted 
during peak flow even when they experienced only a magnetic force of 12 pN. Only 
first pass capturing has been considered as cells returning with the venous blood to 
the heart would are likely to be captured in the lung. 
In patients with PAD, it is likely that the blood flow rates are lower due to their 
condition. Additionally cell aggregation due to dipole interactions at the magnetic flux 
density used is likely to increase targeting efficiency. Nevertheless the best delivery 
protocol might be to stop blood flow for 5 minutes while cells are delivered via a 
catheter which is being retracted. This would increase the targeting efficiency to 
almost 100%. The leg would be placed in the centre of the magnet during cell delivery 
and kept there for another 30 min to allow cell attachment to the artery; such an 
approach should be acceptable from a clinical perspective. This initial cessation of 
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blood flow would allow cells to be attracted to the vessel wall. On reperfusion, the low 
fluid velocities close the boundary permit the magnetic forces to overcome the drag 
force and thus prevent cells from washing away. Another point which needs to be 
considered is that due to the positions of the arteries relative to the centre of the 
Halbach cylinder, cells would be attracted to a half circle of the vessel wall covering 
about 50% of the vessel inner surface. Cells would have to spread out to cover the 
remaining area.  
The strength of the magnetic forces generated is also dependent on the cell 
labelling. All magnet optimisations were performed assuming a cell loading of 15 pg 
iron per cell, which is an amount that has previously been achieved117. For some of the 
CFD simulations were performed with cells loaded with 150 pg iron. Labelling 
concentrations between 10-300 pg iron per cell have been reported previously230 
which indicates that such labelling efficiencies should be achievable. However this 
requires to be tested for the cell line under investigation. 
In order to get a better idea of how cells might behave in the boundary layer of 
the vessel wall, a fluid-structure interaction approach was used. The simulation of a 
single elastic cell being attracted to a surface by magnetic forces acting on each 
vertices and fluid flow around the cell led to the flattening of the cell. This flattening 
together with the magnetic force was sufficient to prevent the cell from flowing away 
but it did not stop the cell from slowly rolling along. Such behaviour is not surprising as 
the vessel wall has been modelled as frictionless. However this abstract model 
highlights that a cell can be held at the vessel wall with magnetic forces generated by 
the selected magnet arrangement. Realistic wall friction and surface receptors on the 
cells themselves will likely generate friction and increase the strength of the cell 
attachment to the vessel wall impeding the cells from rolling along. The contact area 
between cell and vessel wall for the deformable cell would be 30 μm2 while the 
contact area for the case of a rigid sphere is essentially a point, resulting in less friction 
and a less positive outcome in cell attachment. 
One of the major problems for the development of magnetic targeting 
applications is the poor scalability of magnets. This is a consequence of the inverse 
square law behaviour of magnetic fields, which makes it easy to generate sufficient 
force at the scale of a small animal but very difficult to do this for a human. This 
problem has not been addressed sufficiently in the magnetic targeting literature as 
many experiments performed on small animals cannot be scaled up114;122. Nevertheless 
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if theoretical optimisations are first performed with realistic human geometry and 
blood flow data, a scale down can be possible. The best performing magnet design in 
this study could be scaled down for a rabbit arterial injury model such that the forces 
acting on the cells would be similar to those generated for human arteries. However, 
force linearity is limited to a smaller range and blood velocities can only be adjusted by 
selecting an appropriate artery. This choice is additionally restrained by biological 
considerations.  
CFD simulations for the rabbit carotid artery showed that cell capture 
efficiencies under flow are higher than those estimated for human lower leg arteries. 
This is mainly due to the lower mean flow rate and the lower diameter. Even so, the 
scale down would still be valid as the blood flow would have to be stopped for five 
minutes in the rabbit also. As for the human case, cells would have reached the 
boundary layer in this time where the magnetic forces would dominate the fluid 
forces. In this boundary layer, the behaviour of cells would be similar for human and 
rabbit arteries. 
6.5 Conclusions 
For the best performing magnet arrangement (Halbach cylinder k3) in this 
study, the targeting efficiency for all cells passing through the posterior tibial artery 
during one heart beat was 6.25 % (first pass capture). However, if the flow is stopped 
for five minutes a targeting efficiency of close to 100% could be achieved as magnetic 
forces would be strong enough to attract and hold cells at the vessel wall potentially 
increasing cell efficacy. Finally, this magnet can be scaled down for a preclinical rabbit 
injury model without changing the magnetic force acting on the cell. This leads to 
similar behaviour in the boundary layer close to the vessel wall, thus enabling 
development and testing of clinically relevant magnetic cell targeting approaches in an 
animal model. 
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7 Magnetic cell tracking using MRI 
The aim of this chapter is to illustrate the application of MRI for the tracking of 
magnetically labelled cells. Cell tracking using MRI can aim at tracking individual cells 
which are strongly labelled or populations of cells that are weakly labelled. Both of these 
applications will be illustrated by a tissue engineering example with a detection limit of 
less than 10 cells and an in vivo example with a detection limit of approximately 10,000 
cells. The tissue engineering example refers to a project in collaboration with Richard 
Day (UCL Centre for Gastroenterology & Nutrition) for who I did only perform the MRI 
imaging and data analysis. Cell tracking in the rat heart was part of a project with Paolo 
De Coppi (Institute for Child Health (ICH) - Surgery Unit, UCL) to characterise the 
therapeutic potential of rat amniotic stem cells. For this project I performed cell 
labelling, surgery, MRI imaging and data analysis. 
 
  
102 
 
7.1 Introduction 
Labelling cells with superparamagnetic particles increases their magnetic 
susceptibility. If these cells are placed into the magnetic field of an MRI scanner they 
become magnetised and induce local variations in magnetic flux density. Such 
variations in magnetic field homogeneity lead to increased spin-spin relaxation (see 
chapter 3) causing hypointensity on T2 or T2* weighted images. 
 Superparamagnetic particle suspensions (ferrofluids) have been approved as 
contrast agents for the detection of liver and kidney tumours. These contrast agents 
and other SPION have also been used to label cells for in vivo tracking after 
administration in animal models92;174;185;186;189;195;198 and humans103;110;111. Such studies 
showed that cells containing or associated to (bound or absorbed to cell surface) a 
high amount of iron oxide 200-1000 pg a single cell can be detected on MRI images 
with suitable parameters in organs that have a low natural variation in magnetic 
susceptibility such as the brain198. Imaging voxels in such cases are typically in the 50 to 
100 micrometer range for preclinical systems while cells have a diameter of 
approximately 10 micrometer. Detection of these small particles is possible because 
spin-spin relaxation is accelerated up to 100 micrometer away from a particle if the 
time to echo is sufficiently long (TE, an MRI sequence parameter, see chapter 3). 
 However, it is also possible to track cells in organs which are more difficult to 
image such as the moving heart. But for these cases the detection limit is in the range 
of 10 000 cells. This has been demonstrated in studies where weakly labelled cells (< 
15 pg iron oxide per cell) have been tracked in the heart10;188.  
 Another application for which MRI tracking of labelled cells has been proposed 
is the non-invasive assessment of tissue engineered products which contain 
magnetically labelled cells. An example for that is given by Perea et al.143 in a study 
where magnetically labelled cells were seeded onto a vascular scaffold using an 
electromagnet. MRI was used as quality control for the uniformity of cell seeding. 
Another application showed the tracking of labelled cells in tissue engineered 
cartilage251.  
The first section of this study aims to investigate the feasibility of longitudinal 
tracking of labelled stem cells in the rat myocardium after myocardial infarction (MI). 
This is part of an on-going collaboration with Paolo De Coppi (Institute for Child Health 
(ICH) - Surgery Unit, UCL). De Coppi’s laboratory is working on molecular mechanisms 
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of cardiac repair after myocardial infarction. As part of this collaboration I have 
performed the surgery to introduce myocardial infarction in rats as well as cell 
labelling, MRI imaging and data analysis. While the second section will test the 
feasibility to determine cell distributions after magnetic cell seeding on scaffold 
membranes and decellularised intestine samples. This is part of an on-going 
collaboration with Richard Day (UCL Centre for Gastroenterology & Nutrition). For this 
project I did only perform MRI imaging, data analysis and finite element analysis of 
magnetic fields. 
 
The hypotheses for these experiments were: 
 MRI can detect magnetically labelled cells in the rat myocardium and track 
them over time. 
 MRI can be used for the non-invasive assessment of magnetically 
delivered cells on membrane and intestine scaffolds. 
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7.2 Materials and Methods 
7.2.1 Labelling of rat amniotic fluid stem cells 
  Rat amniotic fluid stem cells (rAFSCs) were used for this study. AFSCs are 
sometimes referred to as amniotic MSCs and are similar to the cells used in chapter 
4. Cells were cultured in vitro for 48 hours in Chang medium and then labeled with 
Endorem (Guerbet Laboratories Ltd, UK). Cells were incubated with Endorem SPION 
(20 µl/ml of cell medium) for 24 hours at 37°C and then detached using a 0.05-0.02% 
w/v trypsin sodium-EDTA solution. The labeling concentrations of SPION used were 
selected to preserve > 95% viability (data not shown). Cell viability after cell labeling 
was monitored via trypan blue exclusion. For cell delivery, 5x106 Endorem-labeled 
rAFSCs were re-suspended in 100µl PBS 1X. 
7.2.2 Rat myocardial infarction model and cell transplantation 
The animal study was approved by the Ethics Committee of the University 
College London, UK. All surgical and pharmacological procedures were performed in 
accordance with the animals scientific procedure Act 1986 (Home Office UK). 
Procedures were carried out by myself PIL 70/21740 under the my project licence 
PPL 70/7114. 
  Wistar rats (Harlan Ltd., UK) weighing 250-300g, housed and maintained in a 
controlled environment, were randomly assigned to the cell injection with 
myocardial infarction (MI), cell injection without myocardial infarction (Sham) and a 
control group with myocardial infarction and PBS injection. 
Animals, anesthetised with an intraperitoneal injection of 50 mg/kg body weight of 
ketamine hydrochloride (Vetalor, Parke Davis, NJ) were maintained on a heating 
blanket during surgery at 37°. An endotracheal tube was inserted into the trachea 
and artificial respiration with pure oxygen was provided via a Respirator (Harvard 
Apparatus Ltd., U.K.; 70 strokes/min, tidal volume 8-10 ml/kg). The myocardial 
infarction was performed as follows: the left pectoris major muscle and muscles 
below were dissected and a cardiac access procured via thoracotomy performed in 
the 3rd or 4th intercostal space. The pericardium was removed and the left anterior 
descending coronary artery was occluded (LAD ligation) close to its origin with a 
snare occluder (Mersilk suture 5-0, Ethicon, Johnson & Johnson Ltd. Kirktion, UK) for 
30 minutes. For the Sham group, the suture was put around the LAD but the LAD was 
not occluded. The occlusion was removed and the myocardium re-perfused. After re-
perfusion, labeled cells or PBS control was injected at three sites (33 µl per site) in 
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the border zone of the infarct using 31 gauge needles. In the sham group, injections 
were positioned similar to the MI group. Animals were then fully recovered and 
analgesic (buprenorphine, Vetergesic, 0.25mg/kg Alstoe Ltd, UK) was supplied via 
intraperitoneal injections. 
7.2.3 Serial MRI of infarcted rat hearts 
Animals were subjected to MRI imaging one, two and three weeks after 
surgery. Rats anesthetized with isoflurane 4% (in pure oxygen) and maintained at 2%, 
were placed together with a heating blanket supine on an animal holder. A 
respiration sensor and a cardiac phased array coil (Rapid Biomedical GmbH, 
Germany) were placed on the chest. Needle electrodes were inserted 
subcutaneously into the front limbs to record the electrocardiogram (ECG). For 
cardiac and respiratory gating a MR monitoring and gating system (SA Instruments 
Inc., NY) was used.  
Cardiac imaging was performed with a 9.4T (400 MHz) horizontal bore system 
(Agilent Technologies, Palo Alto, CA) with a shielded gradient system (400 mT/m). A 
short axis image series perpendicular to the long axis orientation was acquired. In 
order to cover the whole left ventricle from apex to base 15 - 20 short axis slices 
were acquired without a gap. A segmented gradient echo sequence was used with 
the following imaging parameters; TE ~1.7 ms, TR ~7.5 ms, FA 15°, FOV 40x40 mm², 
slice thickness 1 mm, Matrix size 192x192. Twenty time frames were recorded for 
every cardiac cycle. A short axis slice was obtained in approximately 45 seconds 
leading to a total scan time for one heart of 10 to 15 minutes. Segment 
(http://segment.heiberg.se) was used to analyze the data and calculate the ejection 
fraction. The same sequence and settings were used for cell tracking but only a single 
frame at the end diastolic time point was acquired. 
7.2.4 Labelling of cells and magnetic seeding with a Halbach cylinder 
Labelling and magnetic seeding of cells was performed by Jordi Gonzales-
Molina (Centre for Gastroenterology & Nutrition, UCL). Nuclepore polycarbonate 
membranes (Whatman, UK; 25 x 80 mm, 10 µm thick) were rolled and inserted into 
50 ml Falcon tubes resulting in coverage of the lumenal surface of the tube. The 
membranes were then coated with 10 µg/ml fibronectin (Sigma-Aldrich).  
A 20 ml cell suspension of 1x106 L929 cells loaded with SPION after 24 hour 
pre-incubation in medium containing 125 µg/ml SPION (fluidMAG-UC/A anionic 
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charged SPION; 50 nm particles with a magnetite core suspended in water; Chemicell 
GmbH, Berlin, Germany) was added to the Falcon tubes containing the polycarbonate 
membranes. The tubes were placed vertically into the Halbach cylinder (see Figure 
25) and incubated at 37°C for 2 hours. 
For dynamic rotational cell seeding, 1x106 SPION labelled L929 cells were 
added to 20 ml MEM in Falcon tubes containing fibronectin-coated polycarbonate 
membranes. The tubes were placed horizontally onto a support and incubated at 37 
°C for 30 minutes before rotating 90° along the horizontal axis. The rotation process 
was repeated three times in total, resulting in a total incubation period of 2 hours.  
After incubation, the polycarbonate membranes were gently washed once 
with 30 ml PBS to remove non-adherent cells and fixed with 2% formaldehyde in 0.1 
M PBS (VWR International Ltd, Lutterworth, UK) for 10 minutes.  
The feasibility of applying the Halbach cylinder device (see Figure 25) to the 
delivery of cells to gastrointestinal tissue was qualitatively evaluated using segments 
of porcine jejunum obtained from an abattoir. After cutting the specimen into 70 mm 
lengths, the mesentery was trimmed away and the lumen rinsed several times with 
PBS before being inverted to expose the mucosa. The mucosal surface was 
mechanically denuded by scraping with the edge of a glass microscope slide before 
rinsing with PBS. The jejuna segments were re-inverted before being positioned into 
50 ml Falcon tubes with stents inserted 1 cm into the ends of each segment so that 
the lumen remained open.  
The tubes were filled with 50 ml of complete medium containing a suspension 
of 1x106 L929 cells pre-incubated with medium containing 125µg/ml SPION for 24 
hours. The tubes were loaded into either the Halbach cylinder (see Figure 25) and 
incubated for 2 hours at 37°C 5% CO2 or placed horizontally onto a support and 
incubated at 37°C for a total 2 hours, with 90° rotation every 30 minutes, as outlined 
above. After incubation, the culture medium was removed and the lumen of the 
jejunum gently washed once with PBS to remove unattached cells, followed by 
fixation in 2% formaldehyde solution for 24 hours. 
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Figure 25: The magnetic seeding device consisted of a bespoke Halbach cylinder (k4 
variety; 12 elements with 120 degree rotation steps for the magnetisation 
orientation; manufactured by Magnet Sales, Swindon, UK). A cylinder (internal 
dimensions: height: 85 mm, diameter: 30 mm) was machined from a solid block of 
aluminium to hold a 50 ml Falcon tube. 12 magnetic rods (neodymium-iron-boron 
magnet NdFeB N48M, remanence magnetisation 1.43 T, intrinsic coercivity 1120 
kA/m length: 75 mm and diameter: 8 mm) were equally spaced around the wall of 
the cylinder. 
7.2.5 Estimation of cell distribution after magnetic cell seeding 
Magnetic resonance imaging (MRI) was used to qualitatively evaluate the 
distribution of SPION labelled cells on polycarbonate membranes and denuded 
jejunum samples (as an example for magnetic cell seeding to thick-walled tissue). The 
lumen of the tubes containing polycarbonate membranes or denuded jejunum was 
filled with 1% low melting point agarose (Fermentas Ltd., Hanover MD, USA) 
containing 8 mM of Gadolinium-DTPA (Magnevist, Bayer AG, Berlin, Germany).  
Imaging was performed on a horizontal bore 9.4 T DirectDrive VNMRS system 
(Agilent Technologies, Palo Alto CA, USA) using a 35 mm quadrature birdcage volume 
coil (RAPID Biomedical GmbH, Würzburg Germany). For 3D imaging, a gradient-echo 
sequence with the following parameters was used: TE 6 ms, TR 25 ms, flip angle 60°, 
3 averages, field of view 35x29x29 mm, matrix size 1000x828x828 leading to an 
isotropic voxel size of 35 μm.  
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Segmentations and 3D renderings were performed using Amira visualisation 
software (v5.2.2, Visage Imaging Inc., Andover MA, USA). The cross-section of the 
tubes was divided into four segments. For each of these segments, hypo-intense 
regions indicative of high iron content were segmented using thresholds. Volume 
rendering without smoothing was performed for all segments and the hypointensity 
volume was recorded.  
7.3 Results 
7.3.1 Longitudinal tracking of labelled cells in the infarcted myocardium  
Imaging the heart poses additional difficulties as MRI is very sensitive to 
motion. In order to avoid motion artefact fast imaging sequences which are 
synchronised to the heart and breathing frequencies have to be used. This limits the 
amount of T2 / T2* weighting that can be used. However, labelled cells can be 
detected if a sufficient amount of cells is injected. Figure 26 A-C shows mid-
ventricular images for a rat at one (A), two (B) and three (C) weeks after surgery. 
White arrows indicate the regions where cells were injected. Although there is a 
slight variation in the exact slice position the persistency of the hypointesnisty can be 
appreciated. Control images for a heart with PBS injection are shown for one (E) and 
three (F) weeks after surgery. The red arrow on image (F) indicates a potential 
limitation of this technique, hypointensity due to hemosiderin (a blood breakdown 
product). Hypointensites can be segmented with localised threshold to estimate the 
distribution volume of labelled cells and to visualise cell distribution (see Figure 26D). 
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Figure 26: In vivo cardiac MRI images of infarcted hearts after cell transplantation. 
Images of magnetically labelled cells injected into the border region of the infarct in 
a rat heart. Images were acquired at one (A), two (B) and three (C) weeks after cell 
transplantation. The white arrows point towards the hypointensities caused by 
injected cells. The scale bare on panel (C) is one centimetre. Local thresholds have 
been used to segment the area containing cells to visualise their distribution in 3D 
(D). Control images for a heart with PBS injection are shown for one (E) and three 
(F) weeks after surgery. The red arrow on image (F) shows a hypointense region on 
a control image which is most likely due to blood breakdown products.  
 
 Serial imaging of transplanted cells allows for the assessment of cell migration 
and cell death. Figure 27 shows the changes in hypointensity volume over time. 
Hearts which did not have an infarct (Sham group) showed lower initial cell retention 
compared to hearts with infarcts (MI group). A general trend indicating a slow 
decline in signal void volume can be appreciated. This decline in hypointensity 
volume is similar for infarcted and non-infarcted hearts.  
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Figure 27: Signal void volume (volume of hypointensity over time) for hearts which 
received cell injections. Rats in the MI group had an infarct (> 20% loss in ejection 
fraction) while rats in the Sham group did not. Infarcted hearts retained more cells 
initially compared to Sham but the decline in the number of voxels with 
hypointensity is similar for both groups. Non error bare are shown for this pilot 
data as each data point is from a single measurements. 
 
7.3.2 Cell distribution after magnetic cell seeding 
For cell seeding with the Halbach cylinder, the signal void volume for different 
segments of the polycarbonate membrane was fairly similar, whereas in the dynamic 
rotational seeding group an accumulation in the segments initially facing down was 
observed (see Figure 28). Membranes with cells attached after delivery by dynamic 
rotational seeding revealed reductions in the amount of SPION labelled cells 
delivered in each quadrant corresponding with each subsequent rotation of the 
membrane. This pattern can be seen on MRI image slices but becomes more obvious 
for segmented 3D rendered volumes (see Figure 28 and Table 4).  
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Figure 28: MRI images and pseudo coloured segmented 3D renderings of 
hypointensities. (A) and (B) are axial and coronal images of the polycarbonate 
membrane where cells have been seeded with the dynamic rotation approach. (C) 
shows a 3D rendering of the segmented hypointensities. The initial position for 
dynamic cell seeding was between the blue and the purple coloured segments. (D), 
(E) and (F) are the corresponding images for magnetic cell seeding with the Halbach 
cylinder. 
The feasibility of using a Halbach cylinder to the delivery of cells to thick-
walled tissue samples was assessed using denuded porcine jejuna. Qualitative 
assessment by MRI of the distribution of cells attached the tissue revealed a uniform 
pattern of distribution similar to that observed with the polycarbonate membranes, 
whereas a non-uniform distribution of cells was observed with the sample loaded by 
dynamic rotation cell seeding (see Figure 29 and Table 4) 
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Figure 29: MRI images and 3D renderings of cells seeded onto porcine jejuna. (A) 
and (C) show axial images for magnetic seeding with a Halbach cylinder and 
dynamic rotation seeding respectively. (B) and (D) show the corresponding volume 
renderings of segmented hypointensities.  
Table 4: Cell distribution after magnetic and dynamic rotational seeding 
 % total SPION loaded cells/sector 
 Purple 
below 
knee 
Blue Red Green 
Halbach cylinder membrane 25.8 23.2 25.0 
7 
26.0 
Dynamic rotational seeding membrane 
 
42.7 34.1 14.0 9.1 
     
Halbach cylinder jejuna 
 
24.6 20.7 27.0 27.7 
Dynamic rotational seeding jejuna 13.4 47.0 28.2 11.4 
 
7.4 Discussion 
7.4.1 Cell tracking in the infarcted rat heart 
The feasibility of magnetic cell tracking in the heart of small animals and 
humans has been demonstrated previously10;186;202;220. However, the image resolution 
of some of these studies was relatively low. Additionally only Stuckey et al.220 
performed volumetric analysis of the hypointensity regions. Such measurements can 
be used for a more precise initial assessment of the success of cell injections. It has 
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previously been reported that T2 / T2* weighted images overestimate the number of 
cells present in an area due to resident macrophages tacking up the SPION of dead 
cells186;187;252. Histological analysis at the end of this current study (outlined in section 
7.2.2) found only a small amount of rat amniotic fluid stem cells. This indicates that the 
observed MRI signal may have originated primarily from macrophages that took up 
free iron oxide particles. However MRI is still useful to estimate the amount of cells 
initially delivered and retained. It is particularly important to relate therapeutic 
outcome to the amount of cells successfully delivered. For example, out of 4 sites in 
the rat heart into which cells have been injected, less than 3 sites seem to have 
retained cells directly after delivery187. This is due to the small myocardial wall in small 
animals which makes direct tissue injection difficult due to cardiac motion. In this 
study a lower initial retention efficiency of labelled cells was observed for sham 
operated hearts (see Figure 27) which is in agreement with previously published 
data187. This is most likely due to the higher interstitial pressure of actively contracting 
myocardium. Even if MRI overestimates the amount of cells present, it may still allow 
estimating the time course of cell clearance over longer time periods as shown in graft 
rejection models189. Also as mentioned in section 2.2.4, MRI offers the highest spatial 
resolution for cell detection and can  be combined with a different imaging modalities, 
which allow for the direct assessment of cell viability such as PET, bioluminescence or 
near infrared imaging173-175;177;179;181. A major advantage of MRI is its non-invasive 
nature which allows for serial assessment of cardiac function253-255 and cell locations. 
Additionally cardiac MRI is more accurate and has a higher reproducibility particular 
for infarcted hearts256 as well as a higher spatial resolution for cell tracking compared 
to SPECT and PET173;192;215.  
The problem of false positive detection of labelled macrophages has received 
some attention and a combination of R2 (1/T2) and R2* (1/T2*) mapping has been 
proposed as a possibility to differentiate between particles internalised in labelled cells 
and free particles195, although this has not been assessed for cardiac imaging. There 
have also been reports about biodegradable iron oxide particle aggregates which lead 
to significant relaxation changes due to reduced aggregate sizes257. It might be possible 
to exploit this if the linker between the particle can be made specific enough such that 
it is only degraded once internalised by macrophages. However, neither of these two 
options has been evaluated in the current study. 
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Another problem frequently encountered in the context of cell delivery is the 
detection of hypointensities due to blood breakdown products196;197. Differentiating 
between them and cells labelled with small amounts of SPION is particular challenging. 
Positive contrast sequences and susceptibility mapping might be able to resolve 
this200;204. However, it is to be seen if these approaches can be made fast and robust 
enough for cardiac imaging. MRI can also be used for the tracking of cells labelled with 
T1 contrast agents
258. However, these T1 based contrast agents are generally not 
compatible with the T2/T2* effects of iron oxide particles used for magnetic delivery 
and are hence not discussed. The short echo times used in this study show that T1 
weighting would not produce positive contrast even if cells would contain a substantial 
amount of a T1 contrast agent. 
7.4.2 Cell tracking for tissue engineered scaffolds 
Our study shows that MRI can be used for the non-destructive assessment of 
cell distributions in tissue engineered scaffolds with high spatial resolution. This 
potential for non-destructive quality control has been demonstrated previously143;251. 
However, these previous examples used fairly low resolutions and could not detect 
less than a few thousand cells in a voxel. The possibility of using MRI to detect single 
cells labelled with micron sized iron oxide particles has been demonstrated previously 
for carefully prepared agarose phantoms259. Our results show that small number of 
cells labelled with iron oxide nanoparticles can detected if the imaging time is 
sufficiently long. A potential advantage is that MRI could also be used to acquire 
additional information such as fibre orientation or elasticity provided the susceptibility 
artefacts due to labelled cells do not interfere in the same scan session. Estimating cell 
distribution in tissue engineered scaffolds is particular suitable when magnetic 
targeting or seeding has been used to position cells. 
As outlined in the introductory section 2.2.4, a major disadvantage for MRI 
based cell tracking is the inability to assess cell viability and differentiation status. 
Although reporter genes for MRI detection of cell viability and differentiation have 
been developed205;207;208, they are not widely used. This is mainly due to the difficulty 
of making these measurements stable enough to use them for routine assessment. 
Even if these problems were to be resolved these markers are not compatible with 
SPION needed for magnetic cell delivery. A potential alternative would be the use of a 
multimodal approach with SPION for spatial localisation and SPECT / PET or 
bioluminescence for sensitive detection of cell viability of differentiation status214-216.  
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7.5 Conclusions 
MRI is ideally suited for magnetic cell tracking particular after magnetic cell 
delivery. Its non-invasive nature allows for cell tracking over time and potential quality 
assessment of tissue engineered grafts. Aside from the need for further technical 
developments to make methods more robust, there is also a need to reduce false 
positive detection of blood related products; a major stepping stone for widespread 
use is the inability to assess cell viability. The only current solution for this problem is 
to use additional non-invasive imaging techniques.  
116 
 
 
8 Conclusions and future directions 
Magnetic cell and drug delivery has the potential to become a useful 
technology to improve treatment efficacy. In order to realise this potential major 
hurdles need to be overcome. This includes technical limitations of insufficient forces 
deep inside the body for external magnets, availability of clinically approved magnetic 
particles and the safety and efficacy of the cell or drug based procedure.  
Chapter 4 and 5 were focused on the potential of an MRI system for magnetic 
targeting. Potential advantages of such an approach are: full magnetisation of particles 
due to high field strength, high spatial and temporal control over magnetic field 
gradients allowing controlled steering of magnetic objects, visualisation of delivery 
success and the possibility for a closed control loop. Experimental results from 
chapters 4 and 5 indicate that cells can be steered in a flow phantom at modest flow 
rates and visualised via MRI. However, to illustrate the clinical potential of such an 
approach it will be necessary to achieve higher targeting efficiencies at high flow rates. 
The experimental results indicate that the major limitation is the weak magnetic force 
acting on cells. Another limitation is the difficulty to track diffusely distributed cells. 
This is particular problematic if active cell guidance has to be used to steer cells 
through several bifurcations. Of course that presupposes the means to accurately 
detect the cell bolus in a few milliseconds which will be difficult. As mentioned in 
chapter 5 cell aggregations can be an advantage as it increases the targeting efficiency. 
However, it could also lead to micro emboli, although there is no direct evidence for 
this as yet. The magnetic cell steering experiments conducted with MRT did not 
included assessments of potential long term effects on the growth and differentiation 
potential of cells. This is a limitation that needs to be addressed if this technique is to 
be used for therapeutic cell delivery. 
Potential future steps for the development of MRI for magnetic delivery are: 
hardware modifications to increase the gradient amplitude, increasing dipole 
interaction forces to generate bigger aggregates, reducing the blood flow velocity, 
improving strategies to allow in vivo magnetofection via MRI, exploiting alternative 
delivery routes, improving the ability to detect labelled cells or drugs in short 
timeframes and assessment of potential long term effects on targeted cells.  
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The available gradient strength is one of the major variables determining 
targeting efficacy. Increasing the gradient strength on preclinical MRI systems is 
certainly feasible but it is questionable if such gradient strengths could be achieved for 
a clinical system. Additional consideration has to be given to the risk of peripheral 
nerve stimulation if high amplitude gradients are switched rapidly. One possibility to 
avoid this problem is the used of dedicated steering gradients which do not comply to 
the stringent criteria of MRI but are optimised for targeting and would hence not 
suffer duty cycle limitations. This would be feasible but would create difficulties if 
imaging is used intermittently to guide particles or cells along. 
In order to use big aggregates due to dipole interaction to increase targeting 
efficiency, we will need a better understanding of the formation of these aggregates 
and their controlled breakdown. Experimental studies at high flux densities with 
different particle sizes, concentrations and shear rates should elucidate these 
questions. Aggregation of labelled cells or drugs could be useful provided that these 
aggregates can be broken down by increased shear rates of small blood vessels or 
actively via other means. In addition, the risk of micro emboli formation should be 
assessed in a suitable animal model. 
Another option would be to reduce the blood flow temporarily to achieve 
higher targeting efficiencies if that is medically acceptable. This might be an easy way 
to increase targeting efficacy. However, it needs to be assessed together with the 
potential delivery device which would be used for such an application. There are also 
practical question of potential aggregation of cells in the delivery device particularly 
when it is introduced into the fringe field of an MRI scanner, as well as questions of 
increased risks to a patient from the movement into the MRI scanner with a delivery 
device placed in a blood vessel. Alternatively the delivery device might be introduced 
into the vasculature while the patient is in the MRI scanner similar to MR based 
vascular interventions. 
The above mentioned points aim at increasing targeting efficiency. 
Alternatively it might be valuable to explore additional applications which would 
increase the value of such a technique. An obvious candidate that comes to mind is 
magnetofection as this would allow non-viral based gen delivery. For example DNA 
conjugated to iron oxide particles could be steered to a site of interest using the 
gradient coils. Following delivery a strong oscillating gradient could be applied in order 
to enhance magnetofection. The ability to perform non-viral DNA delivery would be of 
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considerable clinical interest provided sufficient targeting and transfection efficiencies 
could be achieved. 
Finally alternative routes for drug delivery might be suitable for targeted 
delivery with an MRI system. The most obvious candidate for such an alternative is 
respiratory drug delivery. Aerosol containing magnetic particles can be made with 
sufficient droplet sizes to keep them suspended for several seconds. The low viscosity 
of air should than allow for more efficient steering compared to particles suspended in 
water. This alternative should be explored first in suitable flow phantoms and later in 
an animal model to show the feasibility of such an approach. 
Chapter 6 focused on theoretical optimisations of a magnetic delivery strategy 
based on permanent magnets. It showed that theoretical models can be used to 
compare a range of potential devices and select the best performing one for a 
particular application. Additionally the question of scalability which is one of the major 
stepping stones for magnetic drug and cell delivery has been addressed for that 
particular example. Such theoretical approaches will of course need experimental 
validation but they should allow reducing the parameter space to a tractable size. 
Major limitations of the optimisations performed in Chapter 6 are the idealisation of 
the MRI derived blood vessel geometry, the small number of geometries, the exclusion 
of dipole-dipole interaction as well as hydrodynamic interactions and the lack of 
experimental validation. 
The next steps with regard to the work presented in chapter 6 falls into two 
groups: improving the modelling approach to make it more comprehensive and 
secondly experimental validation of magnetic cell delivery in a suitable animal model. 
The combination of FEM and CFD used for the study presented in Chapter 6 is 
suboptimal particular as it did not include dipole-dipole or hydrodynamic interactions. 
This is a major limitation particular if concentrated solutions of magnetic particles are 
to be simulated. There are examples in the literature which show the integration of 
dipole-dipole interactions into CFD models. Most of these approaches use discrete 
particle models which track each particle individually and estimate their interaction 
with surrounding particles at each time step. This is a possible way to extend the 
models used in chapter 6. However, discrete particle models are computationally very 
expensive and are hence limited to a few hundred to thousand particles. An 
alternative to this approach might be the use of multi scale models where a micro 
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scale model is used to derive particle behaviour. Results from such a model could be 
used to model particle aggregation in the CFD model as the density of a two 
component fluid. Aside from these points the existing models could be used to 
evaluate the potential of magnetic drug delivery to the injured vessel which might be 
useful as an addition or alternative to cell delivery. It might also be of interested to 
perform patient-specific modelling to estimate cell and drug delivery efficiency for a 
clinically relevant patient population. 
As mentioned previously theoretical models do need validation. The next step 
for magnetic cell delivery to arteries with a Halbach cylinder is hence to test this 
approach in an animal model. A rabbit denudation model would be particular suitable 
for that as it is a suitable model for restenosis after angioplasty. A scaled down magnet 
should be manufactured and compared against the FEM simulation results. A suitable 
cell type such as EPCs or MSCs which has the potential to reendothelialise the blood 
vessel after injury need to be selected and a labelling protocol needs to be optimised. 
Following that labelled cells should be delivered with a delivery protocol that is 
feasible for humans. Delivery success and cell distribution should be assessed after 
delivery. Cell distribution and delivery success can be estimated via different means 
but it would be good to test if MRI can be used as it is clinically applicable. These early 
time point assessments are important but the most important outcome measure for 
such a study has to be the degree of restenosis after a sufficient time period for 
example 1 month after cell delivery. This assessment should include the use of 
techniques that can be used clinically. 
Experimental studies could also be conducted for the use of a Halbach cylinder 
for magnetic drug delivery to lower leg arteries after angioplasty. For this experiment 
magnetic particles with a long blood half life time should be loaded with a suitable 
drug such as paclitaxe. Depending on side effects and targeting efficiencies multiple 
drug administration might be feasible. Here the final outcome measure should again 
be the degree of restenosis. Alternatively the delivery of pro angiogenic drugs to 
improve the blood supply in ischemic limbs could be tested. 
The main limitation of the experiments conducted for MRI based cell tracking 
in the ifarcted rat heart are the small number of animals used and the lack of a non-
invasive method for the assessment of cell viability. Additionally the MRI detection 
limit for cells delivery into the heart has not been assessed comprehensively. An 
experimental study should be performed which uses an expression based cell viability 
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marker together with iron oxide nanoparticles. With this combination the status of 
injected cells should be assessed over a typically period for cardiac remodelling (> 6 
weeks in rats). Such a study could also be used to evaluate the potential of R2 and R2* 
maps to differentiate between free and internalised particles. It would also be of 
interest to evaluate potential interference of magnetically labelled cells in the heart 
with commonly used cardiac MRI protocols for the clinical assessment of infracted 
hears such as late Gadolinium enhancement, myocardial strain imaging or stress 
imaging.  
Major limitations of MRI based cell tracking in tissue engineered scaffolds are 
the small number of samples assessed, insufficient assessment of detection limit and 
potential error due to cell aggregation and the used of an additional modality to assess 
cell viability. Similar to the cardiac example the assessment of cell viability and 
potentially differentiation status would be of particular interest. Depending on the 
geometry of the scaffolds a range of non invasive imaging modalities could be used for 
that purpose. A combination of such a modality with MRI in the light of potential 
clinical constrains should be tested to estimate the detection limit and variability of 
such a combined approach. 
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